{"text": "The median time to disease progression was 6.3 months , and the median time to PSA progression was 11.4 months .The median survival period was 15.6 months .", "label": "", "metadata": {}, "score": "26.305319"}
{"text": "The overall disease control rate was 38.3 % .The median overall survival and progression - free survival from the start of second - line therapy were 23 weeks ( 95%CI : 16.6 - 29.5 weeks ) and 12 weeks ( 95%CI : 9.8 - 14.4 weeks ) , respectively .", "label": "", "metadata": {}, "score": "26.892616"}
{"text": "Median time to new metastasis was 7.9 months ( 90 % CI 3.2 - 17.6 months ) , with 6-month and 12-month metastasis - free survival rates of 59 % and 35 % , respectively ( Figure 4 ) .", "label": "", "metadata": {}, "score": "27.938763"}
{"text": "Median progression free survival was 5 months ( confidence interval ( CI ) , % ; 3.59 - 6.40 ) and median overall survival was 10 months ( 95 CI% ; 8.1 - 11.8 ) .", "label": "", "metadata": {}, "score": "30.79892"}
{"text": "The mean follow - up duration was 51 months ( range 5 - 92 ) , and the mean survival was 25.8 months ( 95 % CI 20.4 - 29.3 ) .", "label": "", "metadata": {}, "score": "30.96292"}
{"text": "The median time to disease progression in responding patients was 4 months ( range , 3 to 6 + months ) , whereas the median time to disease progression and survival for all patients who were treated were 3 and 7 months , respectively .", "label": "", "metadata": {}, "score": "33.47219"}
{"text": "Overall objective response rate was 23 % ( 95 % confidence interval : 11 to 39 % ) in all 39 patients evaluated , with a median time to progression of 3 months and overall median survival of 7 months .", "label": "", "metadata": {}, "score": "36.222504"}
{"text": "The median time to progression was 192 days with radiotherapy only compared with 199 days for combined modality therapy ( P greater than 0.2 ) .", "label": "", "metadata": {}, "score": "37.57629"}
{"text": "Approximately 30 - 40 % of localized prostate - cancer patients develop biochemical relapse at 10 years after definitive local treatments [ 1 - 3 ] .", "label": "", "metadata": {}, "score": "37.905445"}
{"text": "Primary trial endpoint was metastasis - free survival .After a median followup of 12.7 years [ 13 ] , adjuvant RT improved the median metastasis - free survival for 1.8 years ( HR 0.71 , 95 % CI 0.54 - 0.94 ; . ) , respectively .", "label": "", "metadata": {}, "score": "40.677715"}
{"text": "A total of 214 patients ( 14 % ) received neoadjuvant and/or concurrent hormonal therapy for a median duration of 4.1 months .Median RT dose was 64.8 Gy .", "label": "", "metadata": {}, "score": "40.749058"}
{"text": "In our study , median TTPP and median time to new metastasis were 2.8 and 7.9 months , respectively .These estimated medians have wide confidence intervals due to the small sample size , but also reflect the heterogeneity of this disease state which has made conducting clinical trials extremely difficult .", "label": "", "metadata": {}, "score": "40.993267"}
{"text": "In a healthy cohort selected for radical prostatectomy the median time from PSA failure to metastasis is 8 years and to death from prostate cancer is more than 10 years [ 4 ] .", "label": "", "metadata": {}, "score": "41.566154"}
{"text": "In patients whose PSA declined to 50 % of baseline on study , PSA progression was defined as a 50 % increase over the nadir and a minimum of 1 ng / mL increase , confirmed by a second value at least 4 weeks later .", "label": "", "metadata": {}, "score": "41.830223"}
{"text": "The 1- ,2- , and 5-year survival rates after thoracic radiation only were 45 % ( Cl , 32 % to 58 % ) , 16 % ( Cl , 6 % to 25 % ) , and 7 % .", "label": "", "metadata": {}, "score": "41.89952"}
{"text": "Disease was improved in 56 % of the patients ( median duration : 13.2 months ) and stabilised in 20 % .Median time to treatment failure was 8.8 months ( 95 % CI : 7.1 - 10.5 ) ; median overall survival from initiating capecitabine was 23.6 months ( 95 % CI : 19.7 - 27.4 ) .", "label": "", "metadata": {}, "score": "41.919144"}
{"text": "Median PFS was 4.0 months for AC and 6.9 months for MVAC .Median survival was 13.2 months for AC and 16.8 months for MVAC .", "label": "", "metadata": {}, "score": "41.9381"}
{"text": "Median PSA doubling time was prolonged from 4.7 months pretreatment to 6.5 months .Median time to PSA progression and new metastasis were 2.8 and 7.9 months , respectively .", "label": "", "metadata": {}, "score": "41.94467"}
{"text": "Five years after RP approximately 45 - 54 % of patients with risk factors remain without evidence of disease without adjuvant RT .This can be estimated from the control arms of the three randomized adjuvant RT trials [ 10 - 12 ] .", "label": "", "metadata": {}, "score": "42.860237"}
{"text": "[ 24 ] reported a median disease specific and overall survival of 54 months and 51 months , respectively , for a population of 129 untreated consecutive patients with androgen independent prostate cancer .", "label": "", "metadata": {}, "score": "43.15854"}
{"text": "A secondary analysis of the RTOG 85 - 31 study reported improved survival for patients with HT treatment duration of more than five years ( in comparison to one to five or less than one years ) [ 18 ] .", "label": "", "metadata": {}, "score": "43.49763"}
{"text": "Median treatment duration was 3.1 months ( range 2.6 - 12.1 months ) .Figure 1 describes the best PSA response of each individual patient on study in a waterfall plot .", "label": "", "metadata": {}, "score": "44.407104"}
{"text": "A Canadian multi - center trial comparing three months versus eight months of neoadjuvant HT in patients with localized prostate cancer has shown a significant overall survival benefit for high risk patients [ 18 ] .", "label": "", "metadata": {}, "score": "44.442253"}
{"text": "Patients received 1 mg warfarin daily to prevent thromboembolism .RESULTSSixty - six patients with progressive AIPC received treatment at 29 centers .Forty - two percent of patients had a 50 % decline in prostate - specific antigen ( PSA ; 95 % confidence interval [ CI ] , 30 - 54 % ) .", "label": "", "metadata": {}, "score": "44.495987"}
{"text": "A particularly unfavourable prognosis was found for patients with a PSA progression after only a few months of HT , indicating a fast resistance to treatment .", "label": "", "metadata": {}, "score": "44.729477"}
{"text": "After a median followup of 6 years , salvage RT alone was associated with a 3-fold increase in prostate - cancer - specific survival compared to those with no salvage treatment ( HR 0.32 , 95 % CI 0.19 - 0.54 ; . )", "label": "", "metadata": {}, "score": "45.12538"}
{"text": "The total median dose to the prostate in the reference point was 50.4Gy at 1.8Gy daily fractions .For EBRT without additional brachytherapy , the same technique was used up to a median dose of 70.2Gy at 1.8Gy fractions .", "label": "", "metadata": {}, "score": "45.128742"}
{"text": "If hormonal therapy is involved , overall survival seems to be a more appropriate endpoint .In principle , by irradiation , the PSA can by decreased to nonmeasurable values in up to 50 % of the cases at 5-year followup [ 9 , 18 ] .", "label": "", "metadata": {}, "score": "45.304207"}
{"text": "Overall , the 6-year progression - free probability ( PFP ) after salvage RT was 32 % .These results suggested the need for salvage RT at the earliest sign of biochemical relapse after RP .", "label": "", "metadata": {}, "score": "46.723297"}
{"text": "Patients .Patients had to have biochemical progression by prostate - specific antigen ( PSA ) levels , despite being treated with androgen deprivation therapy .", "label": "", "metadata": {}, "score": "47.007854"}
{"text": "Discussion .In this study , we identify a subset of men with PSA only recurrences following radiation with or without 6 months of ADT for unfavorable - risk and localized prostate cancer who are unlikely to progress to metastatic disease during their remaining life expectancy despite withholding salvage ADT .", "label": "", "metadata": {}, "score": "47.336533"}
{"text": "The median follow - up period after RT was 68 months .Results .There were no significant differences between different RT concepts ( 6-year OS of 27 % after EBRT and 20 % after EBRT with HDR - BT ) .", "label": "", "metadata": {}, "score": "47.348396"}
{"text": "Median PSA doubling time slowed from 4.7 months at baseline to 6.5 months during the treatment with bevacizumab ( Table 3 ) .Figure 2 : Multiple box plot of the statistics of the PSA distributions at various time points .", "label": "", "metadata": {}, "score": "48.080593"}
{"text": "The median last followup PSA was 3.6 ng / mL ( IQR : 1.8 - 8.3 ) .As shown in Table 1 , men dead at last followup had a median age of 77.3 years at PSA failure compared to 75.7 years for those alive ( . )", "label": "", "metadata": {}, "score": "48.32776"}
{"text": "The median observation period was 24 months ( range , 3 - 74 months ) .The median number of administered DTX cycles was 5 ( range , 2 - 46 cycles ) , and the median DTX administration period was 9 months ( range , 1 - 66 months ) .", "label": "", "metadata": {}, "score": "49.821407"}
{"text": "In mice xenograft models , bevacizumab monotherapy showed suppression of tumor growth and prevention of metastasis [ 18 ] .Phase II trials revealed promising efficacy of bevacizumab containing therapy in metastatic CRPC who had been previously heavily treated with chemotherapies with PSA response rates of 55 - 63 % , objective response rates of 37 - 49 % , and median survival of 9 months or longer [ 11 , 12 ] .", "label": "", "metadata": {}, "score": "49.898846"}
{"text": "Baseline comorbidity at the time of study enrollment was characterized using the ACE-27 instrument [ 9 ] .Prior to PSA failure , men were seen in followup with PSA every 3 months for 2 years , every 6 months until 5 years , and annually thereafter .", "label": "", "metadata": {}, "score": "50.035378"}
{"text": "Results : The median age of the patients was 62 years ( range 26 - 88 ) .Conclusions : Clinical and pathological risk factors in patients with stage II colon cancer may be different in the Turkish population compared to other populations .", "label": "", "metadata": {}, "score": "50.198757"}
{"text": "The survival rates that were found in our study after RT are comparable to studies evaluating the outcome of androgen independent prostate cancer without any recorded local treatment [ 23 , 24 ] .", "label": "", "metadata": {}, "score": "50.337116"}
{"text": "The increase in prostate cancer - specific survival associated with salvage RT was most marked in men with a PSA doubling time of less than 6 months and in patients with a Gleason Score of 8 - 10 .", "label": "", "metadata": {}, "score": "50.647392"}
{"text": "Baseline patient characteristics for patients presenting with PSA progression during primary HT in contrast to other patients treated with one of the mentioned RT concepts in the years 2000 - 2004 are presented in Table 1 .", "label": "", "metadata": {}, "score": "50.913834"}
{"text": "Median time to PSA progression ( TTPP ) was 2.8 months ( 90 % CI 2.4 - 5.4 months ) , with six month TTPP rate of 19 % ( 90 % CI 2 - 36 % ) .", "label": "", "metadata": {}, "score": "50.937134"}
{"text": "A difference was even found for a neoadjuvant HT comparing eight versus three months [ 14 ] .In daily practice , patients sometimes do not receive a well defined short - term neoadjuvant HT before presenting in the radiotherapy department .", "label": "", "metadata": {}, "score": "51.238712"}
{"text": "According to the recommendations of the Prostate Cancer Clinical Trial Working Group [ 18 ] , PSA responses were demonstrated in waterfall plot of decreasing PSA rates for each patient .", "label": "", "metadata": {}, "score": "51.382866"}
{"text": "Randomized trials investigating the role of early versus delayed initiation of ADT in men found at prostatectomy to have lymph node involvement [ 14 ] and those with advanced prostate cancer [ 15 ] showed a survival advantage to the early initiation of ADT .", "label": "", "metadata": {}, "score": "51.49421"}
{"text": "Multivariate analysis identified post - hormone PSA ( PSA nadir before beginning of RT ) , Gleason score , initial PSA and T - stage , not HT duration , as independent predictors of biochemical disease free survival [ 21 ] .", "label": "", "metadata": {}, "score": "51.699654"}
{"text": "All patients received two fractions to deliver 18Gy to the prostate with 7 days between each fraction .Within three weeks after brachytherapy EBRT started .", "label": "", "metadata": {}, "score": "51.731293"}
{"text": "Baseline groups for the categorical variables included radiation alone treatment arm , biopsy Gleason 7 or less , T1 , and no or minimal comorbidity .", "label": "", "metadata": {}, "score": "52.415676"}
{"text": "Of 206 men with unfavorable - risk prostate cancer in a randomized trial of radiation versus radiation and ADT , 53 experienced a PSA failure and were followed without salvage ADT .", "label": "", "metadata": {}, "score": "52.812866"}
{"text": "The outcome after EBRT and HDR - BT was far more favourable if all 332 patients were considered ( 6-year BRFS : 60 % vs. 57 % ; 6-year DFS : 91 % vs. 93 % ; 6-year OS : 77 % vs. 78 % ; median values not reached ) .", "label": "", "metadata": {}, "score": "53.102043"}
{"text": "Three randomized controlled trials investigating the role of adjuvant RT demonstrated improved biochemical control rates [ 10 - 12 ] , whereas metastasis - free survival and overall survival were improved in only one trial after 12.7 years of followup [ 13 ] .", "label": "", "metadata": {}, "score": "53.283577"}
{"text": "Increases of any magnitude during the first 12 weeks were ignored in determining PSA response .Time to Skeletal Related Events [ Time Frame : From randomization up to the cut - off date ( median follow - up of 35.4 months ) ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "53.686417"}
{"text": "The biochemical control at 5 years was approximately 69 - 89 % for adjuvant and only 39 - 68 % for salvage RT .Local control rates were higher than 95 % for adjuvant and 79 - 93 % for salvage treatment .", "label": "", "metadata": {}, "score": "53.777443"}
{"text": "The primary endpoint was biochemical progression - free survival ( bPFS ) .Biochemical relapse was defined as a . ng / mL above postoperative nadir .", "label": "", "metadata": {}, "score": "54.02264"}
{"text": "Overall survival rates were 81 % in the first year , 42.3 % in the third year , and 15.7 % in the fifth year .", "label": "", "metadata": {}, "score": "54.240646"}
{"text": "PubMed View Article .Iversen P , McLeod DG , See WA , Morris T , Armstrong J , Wirth MP : Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer : final results from the bicalutamide early prostate cancer programme at a median follow - up of 9.7 years .", "label": "", "metadata": {}, "score": "54.3071"}
{"text": "The trial was terminated prematurely due to slow accrual .Prior to early closure of the protocol , there were 15 patients entered on the AC regimen and 13 to the MVAC regimen .", "label": "", "metadata": {}, "score": "54.552322"}
{"text": "This validation study exhibited the following characteristics with respect to the ARC : the development group presented with median PSA levels of 110 ng / mL at DTX initiation .", "label": "", "metadata": {}, "score": "54.59597"}
{"text": "Background .The outcome of patients after radiotherapy ( RT ) for localized prostate cancer in case of prostate - specific antigen ( PSA ) progression during primary hormonal therapy ( HT ) is not well known .", "label": "", "metadata": {}, "score": "54.600044"}
{"text": "Overall survival after EBRT with additional HDR - BT boost .Overall survival , stratified by the time to PSA progression after starting hormonal therapy .", "label": "", "metadata": {}, "score": "54.77845"}
{"text": "This single arm multi - institutional phase II trial was a pilot study .Primary endpoints of this study were PSA response rate , time to PSA progression ( TTPP ) , and treatment - related toxicities .", "label": "", "metadata": {}, "score": "55.24575"}
{"text": "Biochemical relapse after radical prostatectomy occurs in approximately 15 - 40 % of patients within 5 years .Postoperative radiotherapy is the only curative treatment for these patients .", "label": "", "metadata": {}, "score": "55.48293"}
{"text": "Results .The median age at failure , interval to PSA failure , and PSA doubling time were 76.6 years ( interquartile range [ IQR ] : 71.8 - 79.3 ) , 49.1 months ( IQR : 37.7 - 87.4 ) , and 25 months ( IQR : 13.1 - 42.8 ) , respectively .", "label": "", "metadata": {}, "score": "55.550472"}
{"text": "We retrospectively analysed 226 patients who had received single - agent capecitabine as 1st - line chemotherapy at our institution .The median interval between breast cancer diagnosis and MBC was 52 months ( range 0 - 479 ) ; 76 % had received endocrine therapy for MBC , 58 % had visceral involvement and 30 % had 3 or more metastatic sites .", "label": "", "metadata": {}, "score": "55.57053"}
{"text": "Postoperative RT demonstrated a significant improvement in bPFS compared to observation ( 74 % versus 52.6 % , hazard ratio ( HR ) 0.48 , 98 % confidence interval ( CI ) 0.37 - 0.62 ; .", "label": "", "metadata": {}, "score": "55.9884"}
{"text": "With a significant impact for biochemical recurrence free survival in multivariate analysis , the PSA nadir could probably become significant in multivariate analysis for disease and overall survival after a longer follow - up interval .", "label": "", "metadata": {}, "score": "56.151733"}
{"text": "Eighty - threepercent had subtotal resection , 58 % had grade 4tumors , and 83 % had performance scores of 0 - 2 .Results : Survival distributions for all patients in thetwo arms were similar , with median survival of41 weeks in each arm .", "label": "", "metadata": {}, "score": "56.213562"}
{"text": "Thereby , the distinction of local versus systemic tumor progression is not compromised , and additional side effects can be avoided .So far , the combination of postoperative RT and hormonal therapy has not been shown to improve overall survival as compared to postoperative RT alone [ 9 , 17 ] .", "label": "", "metadata": {}, "score": "56.371704"}
{"text": "The reference PSA for these declines was a PSA measured within 2 weeks before starting therapy .PSA progression was defined differently for patients who demonstrated a PSA response versus not .", "label": "", "metadata": {}, "score": "56.50514"}
{"text": "Patients with 0 or 1 , 2 , and 3 or 4 risk factors were classified as good- , intermediate- , and poor - risk , respectively .", "label": "", "metadata": {}, "score": "56.561016"}
{"text": "None of the patients had prior chemotherapy , and fourteen patients had prior radiation as a local treatment .Seven patients had a Gleason score of 8 or higher at diagnosis .", "label": "", "metadata": {}, "score": "56.69741"}
{"text": "These cancers have a considerable impact on short term survival rates in contrast to usually expected high disease specific survival rates after definitive curative RT ( 99 % 5-year DSS for patients without initial HT in this study ) .", "label": "", "metadata": {}, "score": "56.805412"}
{"text": "Adjuvant Radiotherapy .Three randomized phase III trials have addressed the benefit of adjuvant RT to the prostatic bed in an immediate postoperative period [ 10 - 12 ] .", "label": "", "metadata": {}, "score": "56.856544"}
{"text": "It is in contrast to other data , emphasizing the higher probability of a local tumor growth with long PSA doubling time and better differentiated cancer , and therefore a better and longer lasting effect on biochemical control [ 23 , 24 ] .", "label": "", "metadata": {}, "score": "56.937866"}
{"text": "However , survival rates were not reported to differ significantly [ 15 , 16 ] .Methods .The indication for a specific treatment was generally based on the patient 's and/or the referring urologist 's preference .", "label": "", "metadata": {}, "score": "57.018772"}
{"text": "Primary trial endpoint was progression - free survival ( PFS ) defined as two consecutive PSA raises above the detection limit of the test used , local or distant recurrence , or death .", "label": "", "metadata": {}, "score": "57.146576"}
{"text": "The good- , intermediate- , and poor - risk groups according to the ARC included 51 ( 65 % ) , 17 ( 22 % ) , and 10 ( 13 % ) patients , respectively .", "label": "", "metadata": {}, "score": "57.176033"}
{"text": "Each analgesic is scored 1 or 4 depending on the analgesic type and dose .AS is the sum of the analgesic scores .Pain progression - free survival ( PFS ) time was measured as the time from the date of randomization up to the date of first pain progression or death due to any cause , whichever occurred first .", "label": "", "metadata": {}, "score": "57.270157"}
{"text": "Until results of these trials become available , the optimal timing and dose of postoperative RT and the value of additional hormonal therapy remain unknown .", "label": "", "metadata": {}, "score": "58.318565"}
{"text": "For those men with either age greater than the median or moderate or severe comorbidities , but not both factors , the 4-year mortality was 39.2 % ( 95 % CI : 22.1%-64.6 % ) .", "label": "", "metadata": {}, "score": "58.422577"}
{"text": "Also , it has been suggested that each Gy increase in total dose may improve the biochemical tumor control by more than 3 % , having doses between 64 and 70 Gy still in the steep part of the dose - response curve [ 29 ] .", "label": "", "metadata": {}, "score": "58.49225"}
{"text": "Thereby , it should be remembered that it needs about 8 years from biochemical recurrence to the development of a clinically measurable progression [ 6 ] .", "label": "", "metadata": {}, "score": "58.549767"}
{"text": "Methods : A total of 238patients with supratentorial grade 3 and grade 4astrocytoma were studied .Patients were stratified by age , extent of surgery , tumor grade , and performance scoreand randomly assigned to receive RT 55 - 60 Gyand either DBD , 200 mg / m2 orally on Days1 - 10 every five weeks or BCNU , 200 mg / m2intravenously every seven weeks .", "label": "", "metadata": {}, "score": "58.553276"}
{"text": "The 3- and 4- year OS survival rates were 26.7 % and 16.7 % , respectively .Conclusion : This study demonstrated that in mCRC patients there may be a significant survival advantage if an adequate tumor response was achieved with all major therapeutic agents .", "label": "", "metadata": {}, "score": "59.0373"}
{"text": "For the purposes of illustration , we subdivided the cohort into three groups based on the median age at failure and the presence of moderate to severe comorbidity and plotted the cumulative incidence of death ( Figure 1 ) .", "label": "", "metadata": {}, "score": "59.191803"}
{"text": "Adjuvant versus Salvage Radiotherapy .The advantages of immediate adjuvant RT are obvious from three randomised trials , achieving a biochemical control at 5 years of more than 20 % higher than from salvage RT [ 10 - 12 , 39 ] .", "label": "", "metadata": {}, "score": "59.333824"}
{"text": "These results are in accordance with the results of our study , demonstrating the independent impact of prognostic factors and post - hormone PSA nadir on biochemical disease free survival .", "label": "", "metadata": {}, "score": "59.402683"}
{"text": "PSA was evaluated after discontinuing therapy at a minimum of every 3 months .Bone scan , CXR or chest CT , and CT scan of abdomen and pelvis were performed every 3 months while on therapy , and after that at physician discretion .", "label": "", "metadata": {}, "score": "59.689743"}
{"text": "Accordingly - corresponding to the results of this study - randomized studies comparing a HDR - BT boost to EBRT in comparison to EBRT alone did not result in an overall survival benefit [ 15 , 16 ] .", "label": "", "metadata": {}, "score": "59.793633"}
{"text": "However , data from randomized controlled trials are lacking .Overall , most clinical data support that a high percentage of patients with rising PSA after RP have a local recurrence .", "label": "", "metadata": {}, "score": "60.12599"}
{"text": "Overall survival ( OS ) time was measured as the time from date of randomization to the date of death due to any cause .The median OS time and its 95.6 % confidence interval were estimated using the Kaplan - Meier method .", "label": "", "metadata": {}, "score": "60.47776"}
{"text": "The DTX treatment was continued until disease progression , unacceptable toxicity , or a patient 's request for its cessation .Disease progression was defined as increases in the number of evaluable lesions observed on imaging tests and/or biological progression characterised by an elevated serum PSA level of 25 % and an absolute increase of 2 ng / mL or higher than the nadir in at least 3 consecutive measurements .", "label": "", "metadata": {}, "score": "60.523266"}
{"text": "Patient Characteristics Stratified by Survival Status .We used descriptive statistics including median values and interquartile range ( IQR ) to characterize the study cohort stratified by survival status .", "label": "", "metadata": {}, "score": "60.530464"}
{"text": "We retrospectively studied a cohort of men with unfavorable - risk localized prostate cancer enrolled in a prospective randomized trial of radiation alone or radiation with 6 months of combined ADT where patient comorbidity at baseline using the ACE-27 comorbidity metric was available [ 8 ] .", "label": "", "metadata": {}, "score": "60.541492"}
{"text": "Most ( n:28 , 77.8 % ) were treated with capecitabine .One patient achieved a complete response and 5 patients had a partial response for an overall response rate of 16.6 % .", "label": "", "metadata": {}, "score": "60.86167"}
{"text": "Regardless of the reason for holding study drug treatment , the maximum allowable length of treatment interruption was 2 months .Evaluation .Blood pressure and proteinuria were monitored every two weeks and 4 weeks , respectively .", "label": "", "metadata": {}, "score": "60.86866"}
{"text": "The timing of initiating ADT following postradiation PSA failure , however , remains an unanswered question .Factors associated with improved outcomes following PSA failure after local therapy include prolonged time to failure [ 5 ] , slower PSA doubling time [ 6 ] , and lower Gleason score [ 7 ] .", "label": "", "metadata": {}, "score": "61.117844"}
{"text": "416 - 419 , 2001 .View at Google Scholar \u00b7 View at Scopus . A. A. Caire , L. Sun , O. Ode et al . , \" Delayed prostate - specific antigen recurrence after radical prostatectomy : how to identify and what are their clinical outcomes ? \"", "label": "", "metadata": {}, "score": "61.627808"}
{"text": "Patients with prostate cancer who developed PSA recurrence after local therapy were included if they had absence of bone or visceral metastases and PSA progression despite androgen deprivation therapy .", "label": "", "metadata": {}, "score": "61.914513"}
{"text": "Oefelein MG , Agarwal PK , Resnick MI : Survival of patients with hormone refractory prostate cancer in the prostate specific antigen era .J Urol 2004 , 171 : 1525 - 1528 .", "label": "", "metadata": {}, "score": "61.949165"}
{"text": "Patients with evidence of macroscopic recurrence or metastatic disease are excluded .It is estimated to enroll 350 patients , and the trial is currently recruiting patients .", "label": "", "metadata": {}, "score": "62.16025"}
{"text": "Background and Purpose .Life expectancy data could identify men with favorable post - radiation prostate - specific antigen ( PSA ) failure kinetics unlikely to require androgen deprivation therapy ( ADT ) .", "label": "", "metadata": {}, "score": "62.171307"}
{"text": "G. J. Bubley , M. Carducci , W. Dahut et al . , \" Eligibility and response guidelines for phase II clinical trials in androgen - independent prostate cancer : recommendations from the prostate - specific antigen working group , \" Journal of Clinical Oncology , vol .", "label": "", "metadata": {}, "score": "62.409836"}
{"text": "The optimal dose and timing of postoperative RT is subject of national and international phase III trials .Outside of clinical trials , 60 - 64 Gy should be used in the immediate postoperative setting and 64 - 72 Gy in the salvage setting , dependent on the absence or presence of macroscopic recurrence .", "label": "", "metadata": {}, "score": "62.606747"}
{"text": "There was no late grade 4 toxicity reported and the 5-year actuarial incidence of late grade 3 toxicity was 4.2 % in the RT group and 2.6 % in the observation arm ( .", "label": "", "metadata": {}, "score": "62.629047"}
{"text": "Svatek R , Karakiewicz PI , Shulman M , Karam J , Perrotte P , Benaim E : Pre - treatment nomogram for disease - specific survival of patients with chemotherapy - naive androgen independent prostate cancer .", "label": "", "metadata": {}, "score": "62.842754"}
{"text": "A modified version of the regimen used in the SWOG9916 study [ 2 ] was used as the DTX treatment protocol [ 17 ] .Briefly , DTX ( 60 mg / m 2 ) was administered by intravenous drip infusion for 1 hour on day 1 , once every 3 - 4 weeks .", "label": "", "metadata": {}, "score": "62.868256"}
{"text": "From several trials , nomograms have been created to assess the risk of an individual patient for tumor progression [ 8 , 9 ] .This documents the importance of adequate selection of men after curative intended local treatment of prostate cancer .", "label": "", "metadata": {}, "score": "62.917595"}
{"text": "Trock et al .analyzed 635 patients undergoing RP in the years of 1982 to 2004 who experienced biochemical and/or local recurrence and received either no salvage treatment ( . ) , respectively [ 17 ] .", "label": "", "metadata": {}, "score": "63.028046"}
{"text": "The development of a measurable local recurrence should be avoided , because in these patients outcome after salvage RT seems to be worse [ 18 , 21 , 22 ] .", "label": "", "metadata": {}, "score": "63.092415"}
{"text": "PubMed View Article .Armstrong AJ , Garrett - Mayer ES , Yang YCO , de Wit R , Tannock IF , Eisenberger M : A contemporary prognostic nomogram for men with hormone - refractory metastatic prostate cancer : a TAX327 study analysis .", "label": "", "metadata": {}, "score": "63.353382"}
{"text": "Adjuvant RT was well tolerated ; however , urinary incontinence was more common after RT ( 6.5 % ) compared to observation ( 2.8 % ) ( . )", "label": "", "metadata": {}, "score": "63.369495"}
{"text": "During the observation period , death occurred in 39 patients ( 46 % ) , of whom 18 , 14 , and 7 were in the good- , intermediate- , and poor - risk groups , respectively .", "label": "", "metadata": {}, "score": "63.40773"}
{"text": "Results : The survival analyses of all the patients did not demonstrate any differences in OS or DFS in obese as compared to non - obese patients .", "label": "", "metadata": {}, "score": "63.451065"}
{"text": "[ 19 , 27 , 33 , 38 ] .However , the dose - dependent effect has never been prospectively assessed both in the adjuvant or salvage setting .", "label": "", "metadata": {}, "score": "63.480007"}
{"text": "An initial detailed questionnaire was administered to approximately 150 patients with advanced cancer .This questionnaire was subsequently revised and given to a total of 1,115 patients with advanced colorectal or lung cancer .", "label": "", "metadata": {}, "score": "63.649296"}
{"text": "A total of 36 variables showed statistically significant prognostic information for survival in univariate analyses , even though many of these variables were associated with only a minimal increase in risk .", "label": "", "metadata": {}, "score": "63.70979"}
{"text": "Unfortunately clinical outcome of the subgroup of patients in the observational arm who ultimately received salvage RT for either increasing PSA or a local recurrence ( 70 patients , mean PSA value 1.0 ng / mL ) is not provided .", "label": "", "metadata": {}, "score": "63.74347"}
{"text": "235 - 246 , 1997 .M. R. Smith , F. Kabbinavar , F. Saad et al . , \" Natural history of rising serum prostate - specific antigen in men with castrate nonmetastatic prostate cancer , \" Journal of Clinical Oncology , vol .", "label": "", "metadata": {}, "score": "63.756054"}
{"text": "However , patients with a postoperative . ) , although the relative improvement of immediate postoperative irradiation was still the same .This stresses the value of early adjuvant RT before development of PSA recurrence .", "label": "", "metadata": {}, "score": "63.789932"}
{"text": "110 , no . 7 , pp .1417 - 1428 , 2007 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . E. S. Antonarakis , Z. Feng , B. J. Trock et al . , \" The natural history of metastatic progression in men with prostate - specific antigen recurrence after radical prostatectomy : long - term follow - up , \" BJU International , vol .", "label": "", "metadata": {}, "score": "63.81155"}
{"text": "After disease progression , participants were to be followed every 3 months until death or the study cutoff date , whichever came first .The study cut - off date was event - driven and was defined as the date when 873 deaths had occurred .", "label": "", "metadata": {}, "score": "63.889496"}
{"text": "Atrasentan improved time to disease progression ( similar definition to the time to new metastasis in our study ) from 22.4 months to 25.5 months , but the difference was not statistically significant ( .", "label": "", "metadata": {}, "score": "63.95092"}
{"text": "PubMed View Article .Lancet Oncol 2011 , 12 : 451 - 459 .PubMed View Article .Alexander AA , Crook J , Jones S , Malone S , Bowen J , Truong P , Pai H , Ludgate C : Is biochemical response more important than duration of neoadjuvant hormone therapy before radiotherapy for clinically localized prostate cancer ?", "label": "", "metadata": {}, "score": "63.956566"}
{"text": "M. Han , A. W. Partin , M. Zahurak , S. Piantadosi , J. I. Epstein , and P. C. Walsh , \" Biochemical ( prostate specific antigen ) recurrence probability following radical prostatectomy for clinically localized prostate cancer , \" Journal of Urology , vol . 169 , no . 2 , pp .", "label": "", "metadata": {}, "score": "64.58077"}
{"text": "An absolute blood count was carried out every 3 weeks , 1 - 3 days before planned chemotherapy cycle .Overall , 1238 cycles were delivered .", "label": "", "metadata": {}, "score": "64.686935"}
{"text": "The last PSA level had to be a minimum value of 1 ng / mL , measured within two weeks prior to registration .If the patient was on antiandrogen therapy , then PSA progression after the withdrawal period ( a minimum of 28 days for flutamide and 42 days for bicalutamide or nilutamide ) was required .", "label": "", "metadata": {}, "score": "64.860565"}
{"text": "In summary , our data suggest that older , less healthy men with both long intervals to PSA failure and PSA doubling times can safely be spared the morbidity of life - long ADT following postradiation PSA failure .", "label": "", "metadata": {}, "score": "64.92406"}
{"text": "With the preliminary efficacy data in metastatic prostate cancer and the established tolerability of bevacizumab , it led to the rationale of evaluating the agent in an earlier setting of nonmetastatic disease .", "label": "", "metadata": {}, "score": "64.92612"}
{"text": "Two treatment - related deaths occurred ; one from sepsis and one from renal failure .Thus , this regimen , as second - line chemotherapy for women with metastatic breast cancer , resulted in moderate , short - term , antitumor activity at the expense of marked toxicity .", "label": "", "metadata": {}, "score": "65.0365"}
{"text": "11 - 16 , 2011 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .R. A. Madan , J. L. Gulley , J. Schlom et al . , \" Analysis of overall survival in patients with nonmetastatic castration - resistant prostate cancer treated with vaccine , nilutamide , and combination therapy , \" Clinical Cancer Research , vol .", "label": "", "metadata": {}, "score": "65.05116"}
{"text": "We attempted to adjust for this issue by including PSA doubling time in the multivariable model .Second , with 53 men , the study is not large enough to draw definitive conclusions about all men in whom salvage ADT can be withheld ; in older and less healthy men , the data appear robust enough to make this recommendation .", "label": "", "metadata": {}, "score": "65.05702"}
{"text": "Progression Free survival ( PFS ) time was measured as the time from the date of randomization up to the date of occurrence of the first event defining a disease progression or death due to any cause , whichever occurred first .", "label": "", "metadata": {}, "score": "65.07132"}
{"text": "PubMed Central PubMed View Article .J Clin Oncol 2008 , 26 : 1148 - 1159 .PubMed View Article .Armstrong AJ , Garrett - Mayer E , de Wit R , Tannock I , Eisenberger M : Prediction of survival following first - line chemotherapy in men with castration - resistant metastatic prostate cancer .", "label": "", "metadata": {}, "score": "65.200005"}
{"text": "Before they were randomized , patients were stratified by ECOG performance score , histologic type , maximum tumor diameter , and NCCTG institution .Radiotherapy consisted of a total of 5000 cGy in 5 weeks with a 1000 cGy boost in 5 fractions to a small tumor field .", "label": "", "metadata": {}, "score": "65.20777"}
{"text": "Subgroup analysis after a central pathology review demonstrated that patients with positive resection margins benefitted most from adjuvant RT [ 14 ] .But this conclusion was only achieved by a detailed central pathological review , emphasizing the disagreement both on the detection of positive margins and definition of differentiation of the tumor by different pathologists .", "label": "", "metadata": {}, "score": "65.21078"}
{"text": "Materials and Methods .Initial Treatment , Followup and Description of the Study Cohort .The cohort is comprised of men enrolled in a randomized trial of radiation or radiation with 6 months of combined ADT [ 8 ] .", "label": "", "metadata": {}, "score": "65.25409"}
{"text": "The toxicity rates were low .No patient experienced grade 4 toxicity .Two patients in the RT arm developed a urethral stricture .Salvage Radiotherapy . , positive margins , and negative pelvic lymph nodes [ 9 , 16 ] .", "label": "", "metadata": {}, "score": "65.36699"}
{"text": "None of these patients developed a febrile neutropaenia .Haematopoietic support ( granulocyte colony - stimulating factor ( G - CSF ) ) was required in 12 cycles .", "label": "", "metadata": {}, "score": "65.38818"}
{"text": "Due to the small sample sizes , time to event statistics ( e.g. , median , 6 month rate , etc . ) were estimated more conservatively using linear interpolation among successive event times on the Kaplan - Meier curves [ 15 ] .", "label": "", "metadata": {}, "score": "65.482285"}
{"text": "The risk factor of bone scan progression was subject to satisfaction that a bone scan had been performed at DTX initiation , comparable prior bone scans had also been performed , and progression or increases in the numbers of hot spots were demonstrated by these scans .", "label": "", "metadata": {}, "score": "65.57388"}
{"text": "Tumor characteristics and tumor burden were considered to be predictive markers of the therapeutic efficacy of bevacizumab .The medical records of 705 patients with mCRC were retrospectively reviewed in three oncology centers between January , 2005 and September , 2012 .", "label": "", "metadata": {}, "score": "65.683014"}
{"text": "The body mass index ( BMI ) of 112 TNBC patients was calculated with weight at the time of diagnosis and height .After a mean follow - up of 23.2 \u00b1 15.5 months , there were 12 recurrences ( 10.71 % ) and 6 deaths ( 5.35 % ) .", "label": "", "metadata": {}, "score": "65.718864"}
{"text": "The decision for a local RT should be made considering this prognosis .This is a retrospective analysis in a consecutively treated patient population , so that limitations exist due to a variety of underlying confounding factors .", "label": "", "metadata": {}, "score": "65.78041"}
{"text": "There were no significant differences between different RT concepts ( 6-year OS of 27 % after EBRT and 20 % after EBRT with HDR - BT ) .", "label": "", "metadata": {}, "score": "65.868805"}
{"text": "Bevacizumab 10 mg / kg intravenously was administered every 14 days until PSA progression , development of metastasis , or unacceptable toxicity .Results .15 patients were enrolled and treated with bevacizumab for a median duration of 3.1 months .", "label": "", "metadata": {}, "score": "66.044525"}
{"text": "Only Gleason score was found to be significantly relevant for ( disease specific and overall ) survival in our patient population .However , additionally to the Gleason score and patient age , only PSA progression during HT remained a significant predictor for survival in the multivariate analysis .", "label": "", "metadata": {}, "score": "66.07087"}
{"text": "The use of adjuvant RT after RP in patients with adverse risk factors has demonstrated improved biochemical control and overall survival .However , there is a relevant risk of overtreatment as patients might be included who are cured by surgery alone .", "label": "", "metadata": {}, "score": "66.10946"}
{"text": "Including specific high - risk subsets , based on Gleason Score or PSA doubling time criteria , may help limit the heterogeneity in the study population .", "label": "", "metadata": {}, "score": "66.14378"}
{"text": "PSA progression - free survival ( PFS ) time was defined as the time from the date of randomization up to the date of the first documented PSA progression or death due to any cause , whichever occurred first .", "label": "", "metadata": {}, "score": "66.18855"}
{"text": "Therefore , the results of the 15 eligible and treated patients are reported here .The baseline characteristics of the study participants are summarized in Table 1 .", "label": "", "metadata": {}, "score": "66.197525"}
{"text": "PubMed View Article .Yu JB , Makarov DV , Sharma R , Peschel RE , Partin AW , Gross CP : Validation of the partin nomogram for prostate cancer in a national sample .", "label": "", "metadata": {}, "score": "66.20712"}
{"text": "PubMed View Article .Smaletz O , Scher HI , Small EJ , Verbel DA , McMillan A , Regan K , Kelly WK , Kattan MW : Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration .", "label": "", "metadata": {}, "score": "66.22188"}
{"text": "The research sample consisted of a total of 44 patients ( 22 control and 22 intervention group ) .Conclusion We provided a better symptom control , improved the patient s quality of life ( excluding physical and congnitive functions ) , and patient and family satisfaction levels were higher in the palliative care based case management intervention group , but direct health costs were not affected .", "label": "", "metadata": {}, "score": "66.31401"}
{"text": "The European Organisation for the Research and Treatment of Cancer ( EORTC ) trial 22911 [ 10 ] included 1005 patients between 1992 and 2001 either having had pT3a , pT3b , or R1 .", "label": "", "metadata": {}, "score": "66.32567"}
{"text": "Lacking results from a randomized Canadian trial of early versus delayed ADT in men with PSA failure following radiation ( NCT00439751 ) , decisions are typically made today in the context of comorbidity and adverse prostate cancer prognostic factors such as PSA doubling time and time to PSA failure .", "label": "", "metadata": {}, "score": "66.43475"}
{"text": "All patients had a pretreatment PSA measurement .PSA data since the initial diagnosis were collected retrospectively from the referring urologist , including the start of HT and PSA nadir value .", "label": "", "metadata": {}, "score": "66.49067"}
{"text": "Kawahara T , Miyoshi Y , Sekiguchi Z , Sano F , Hayashi N , Teranishi J , Misaki H , Noguchi K , Kubota Y , Uemura H : Risk factors for metastatic castration - resistant prostate cancer ( CRPC ) predict long - term treatment with docetaxel .", "label": "", "metadata": {}, "score": "66.7697"}
{"text": "4 , pp .1282 - 1286 , 2005 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .T. M. Pisansky , T. F. Kozelsky , R. P. Myers et al . , \" Radiotherapy for isolated serum prostate specific antigen elevation after prostatectomy for prostate cancer , \" Journal of Urology , vol .", "label": "", "metadata": {}, "score": "66.772766"}
{"text": "PubMed View Article .Minato A , Fujimoto N , Kubo T , Harada S , Akasaka S , Matsumoto T : Efficacy of estramustine phosphate according to risk classification of castration - resistant prostate cancer .", "label": "", "metadata": {}, "score": "66.87422"}
{"text": "Both increasing age at PSA failure ( HR : 1.14 ; 95 % CI : 1.03 - 1.25 ; . ) were significantly associated with an increased risk of death .", "label": "", "metadata": {}, "score": "66.93579"}
{"text": "10 , pp .2077- 2085 , 2011 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .M. R. Smith , F. Saad , R. Coleman et al . , \" Denosumab and bone - metastasis - free survival in men with castration - resistant prostate cancer : results of a phase 3 , randomised , placebo - controlled trial , \" The Lancet , vol .", "label": "", "metadata": {}, "score": "66.99185"}
{"text": "Chemotherapy was followed by identical thoracic radiotherapy 4 weeks after the second cycle of chemotherapy .Four weeks after thoracic radiotherapy was completed , patients received another two cycles of identical chemotherapy .", "label": "", "metadata": {}, "score": "67.29486"}
{"text": "HT is frequently administered before brachytherapy for downsizing the prostate volume [ 13 ] .The optimal sequencing and duration of HT in combination with EBRT is not well known .", "label": "", "metadata": {}, "score": "67.366394"}
{"text": "PubMed View Article .Prada PJ , Mendez L , Fern\u00e1ndez J , Gonz\u00e1lez H , Jim\u00e9nez I , Arrojo E : Long - term biochemical results after high - dose - rate intensity modulated brachytherapy with external beam radiotherapy for high risk prostate cancer .", "label": "", "metadata": {}, "score": "67.42479"}
{"text": "PubMed View Article .Nakano K , Ohta S , Komatsu K , Kubo T , Nukui A , Suzuki K , Kurokawa S , Kobayashi M , Morita T : Docetaxel with or without estramustine for estramustine refractory castration - resistant prostate cancer : a single institution experience .", "label": "", "metadata": {}, "score": "67.48668"}
{"text": "The toxicity and morbidity of urethral stenosis and incontinence can be abstained by starting RT years after full recovery from RP .There have been multiple retrospective clinical trials comparing the influence of either immediate adjuvant or salvage RT on local control and/or biochemical control [ 40 ] .", "label": "", "metadata": {}, "score": "67.50234"}
{"text": "19 , pp .2329 - 2335 , 2006 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .T. Wiegel , D. Bottke , U. Steiner et al . , \" Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate - specific antigen : ARO 96 - 02/AUO AP 09/95 , \" Journal of Clinical Oncology , vol .", "label": "", "metadata": {}, "score": "67.51609"}
{"text": "Increases in PPI or AS during the first 12 weeks were ignored in determining pain response .Functional Assessment of Cancer Therapy - Prostate ( FACT - P ) is a 39-item participant questionnaire that measures the concerns of patients with prostate cancer .", "label": "", "metadata": {}, "score": "67.55682"}
{"text": "Two men underwent salvage brachytherapy for a local only recurrence .and constitute the study cohort .At the time of PSA failure , all men had restaging with bone scan .", "label": "", "metadata": {}, "score": "67.56367"}
{"text": "PubMed View Article .Halabi S , Small EJ , Kantoff PW , Kattan MW , Kaplan EB , Dawson NA , Levine EG , Blumenstein BA , Vogelzang NJ : Prognostic model for predicting survival in men with hormone - refractory metastatic prostate cancer .", "label": "", "metadata": {}, "score": "67.68155"}
{"text": "Forty percent of US patients discontinued the treatment prematurely primarily due to rising PSA whereas only 21.9 % of the patients in other countries did so .", "label": "", "metadata": {}, "score": "67.82439"}
{"text": "The Southwest Oncology Group ( SWOG )8794 trial [ 11 ] included 425 pT3a , pT3b or R1 patients between 1988 and 1997 .Patients received either adjuvant RT to the prostatic fossa with 60 - 64 Gy or were observed .", "label": "", "metadata": {}, "score": "67.87112"}
{"text": "Ultimately , it will take the results of randomized trials where comorbidity is stratified for to definitively answer the question of when and in whom ADT is beneficial following PSA failure .", "label": "", "metadata": {}, "score": "67.910255"}
{"text": "At least 4 weeks had to have elapsed since prior systemic therapy , except for LHRH analogue therapy and steroids .Patients were required to use effective means of contraception .", "label": "", "metadata": {}, "score": "68.09979"}
{"text": "Unfortunately , progression on ADT eventually occurs , that is , nonmetastatic castrate - resistant prostate cancer ( CRPC ) , and after that , this patient population is likely to continue progression to metastatic disease .", "label": "", "metadata": {}, "score": "68.27261"}
{"text": "Randomized trials are currently investigating the role of adjuvant and salvage radiotherapy .Patients with biochemical relapse after prostatectomy should at the earliest sign of relapse be referred to salvage radiotherapy and should preferably be treated within a clinical trial .", "label": "", "metadata": {}, "score": "68.29273"}
{"text": "These studies did not investigate the role of comorbidity .While this study is strengthened by the use of prospectively collected data on men who were enrolled in a randomized trial , it has several potential limitations .", "label": "", "metadata": {}, "score": "68.35445"}
{"text": "23 , pp .2335 - 2342 , 2004 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .C. J. Allegra , G. Yothers , M. J. O'Connell et al . , \" Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon : results of NSABP protocol C-08 , \" Journal of Clinical Oncology , vol .", "label": "", "metadata": {}, "score": "68.41831"}
{"text": "Antiandrogen hormonal therapy is frequently combined with different RT methods .Treatment concepts are often based on the results of randomized trials , particularly for high risk patients receiving EBRT as a single modality [ 9 - 11 ] .", "label": "", "metadata": {}, "score": "68.465515"}
{"text": "17 , pp .1591 - 1597 , 1999 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .S. F. Slovin , A. S. Wilton , G. Heller , and H. I. Scher , \" Time to detectable metastatic disease in patients with rising prostate - specific antigen values following surgery or radiation therapy , \" Clinical Cancer Research , vol .", "label": "", "metadata": {}, "score": "68.62374"}
{"text": "Two trials have been initiated in the late eighties and early nineties of the last century , using old 2 D radiation techniques , and none of these trials provided details of the performed lymph node dissection .", "label": "", "metadata": {}, "score": "68.66034"}
{"text": "PubMed View Article .Souhami L , Bae K , Pilepich M , Sandler H : Impact of the duration of adjuvant hormonal therapy in patients with locally advanced prostate cancer : a secondary analysis of RTOG 85 - 31 .", "label": "", "metadata": {}, "score": "68.748825"}
{"text": "2918 - 2925 , 2005 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .M. R. Smith , R. Cook , K. A. Lee , and J. B. Nelson , \" Disease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castration - resistant nonmetastatic prostate cancer , \" Cancer , vol .", "label": "", "metadata": {}, "score": "68.80282"}
{"text": "Faria and colleagues reported on a cohort of 285 men who underwent external beam radiation with or without ADT and experienced a biochemical failure [ 16 ] .", "label": "", "metadata": {}, "score": "68.85969"}
{"text": "PubMed View Article .Armstrong AJ , Tannock IF , de Wit R , George DJ , Eisenberger M , Halabi S : The development of risk groups in men with metastatic castration - resistant prostate cancer based on risk factors for PSA decline and survival .", "label": "", "metadata": {}, "score": "68.878784"}
{"text": "Table 1 : Comparison of the distribution of the clinical characteristics at the time of initial treatment and at PSA failure for the 53 men in the study cohort stratified by survival status at time of last followup .", "label": "", "metadata": {}, "score": "69.098495"}
{"text": "960 - 963 , 1999 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .W. K. Kelly , S. Halabi , M. A. Carducci , et al . , \" Randomized , double - blind , placebo - controlled phase iii trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration - resistant prostate cancer : CALGB 90401 , \" Journal of Clinical Oncology , vol .", "label": "", "metadata": {}, "score": "69.19588"}
{"text": "142 - 146 , 2006 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .T. L. Klayton , K. Ruth , M. K. Buyyounouski et al . , \" Prostate - specific antigen doubling time predicts the development of distant metastases for patients who fail 3-dimensional conformal radiotherapy or intensity modulated radiation therapy using the Phoenix definition , \" Practical Radiation Oncology , vol .", "label": "", "metadata": {}, "score": "69.29508"}
{"text": "Patients on anticoagulants were allowed if they had been on therapy for at least 4 weeks and had no acute thromboembolic activity .Patients had to have recovered from any major surgical procedure , open biopsy , or significant traumatic injury without serious , nonhealing wound , ulcer , or bone fracture , and a minimum time interval of 28 days must have elapsed from any major surgery .", "label": "", "metadata": {}, "score": "69.50615"}
{"text": "202 - 208 , 2006 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .C. R. Pound , A. W. Partin , M. A. Eisenberger , D. W. Chan , J. D. Pearson , and P. C. Walsh , \" Natural history of progression after PSA elevation following radical prostatectomy , \" Journal of the American Medical Association , vol .", "label": "", "metadata": {}, "score": "69.53991"}
{"text": "In the absence of results from randomized trials , the potentially improved local tumor control by higher RT dose should be carefully weighted out against possibly increased toxicity .", "label": "", "metadata": {}, "score": "69.6727"}
{"text": "References .M. Han , A. W. Partin , S. Piantadosi , J. I. Epstein , and P. C. Walsh , \" Era specific biochemical recurrence - free survival following radical prostatectomy for clinically localized prostate cancer , \" The Journal of Urology , vol .", "label": "", "metadata": {}, "score": "69.680626"}
{"text": "51 - 60 , 2001 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .O. K. MacDonald , S. E. Schild , S. Vora et al . , \" Salvage radiotherapy for men with isolated rising PSA or locally palpable recurrence after radical prostatectomy : do outcomes differ ? \"", "label": "", "metadata": {}, "score": "69.69667"}
{"text": "Conclusions .PSA progression during initial antiandrogen hormonal therapy was found to be independently associated with an unfavorable prognosis after local radiotherapy for prostate cancer .", "label": "", "metadata": {}, "score": "69.95144"}
{"text": "In contrast , adjuvant RT did not negatively impact erectile dysfunction [ 15 ] .ARO 96 - 02/AUO AP 09/05 Trial .The \" Arbeitsgemeinschaft Radiologische Onkologie ( ARO ) und Urologische Onkologie ( AUO ) \" of the German Cancer Society included 388 pT3 - 4pN0M0 patients into the trial [ 12 ] .", "label": "", "metadata": {}, "score": "69.97642"}
{"text": "143 , no . 2 , pp .401 - 409 , 1993 .View at Google Scholar \u00b7 View at Scopus .O. Melnyk , M. Zimmerman , K. J. Kim , and M. Shuman , \" Neutralizing anti - vascular endothelial growth factor antibody inhibits further growth of established prostate cancer and metastases in a pre - clinical model , \" The Journal of Urology , vol .", "label": "", "metadata": {}, "score": "70.01926"}
{"text": "View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .J. F. Pazona , M. Han , S. A. Hawkins , K. A. Roehl , and W. J. Catalona , \" Salvage radiation therapy for prostate specific antigen progression following radical prostatectomy : 10-Year outcome estimates , \" Journal of Urology , vol .", "label": "", "metadata": {}, "score": "70.22531"}
{"text": "Table 3 .Univariate and multivariate analysis for overall survival of major prognostic factors .Abbreviations : CI , confidence interval ; PSA , prostate - specific antigen ; PSADT , prostate - specific antigen doubling time ; ECOG , Eastern Cooperative Oncology Group ; ALP , alkaline phosphatase .", "label": "", "metadata": {}, "score": "70.2534"}
{"text": "Overall survival ( OS ) was defined as the period from DTX initiation to death .When patients were lost to follow - up , OS was considered up to the last day of confirmed patient survival .", "label": "", "metadata": {}, "score": "70.29193"}
{"text": "18 , pp .2924 - 2930 , 2009 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .I. M. Thompson , C. M. Tangen , J. Paradelo et al . , \" Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival : long - term followup of a randomized clinical trial , \" Journal of Urology , vol .", "label": "", "metadata": {}, "score": "70.35137"}
{"text": "Secondary endpoints included overall survival ( OS ) and time to metastatic disease which was measured as the time from registration to the first clinical or radiologic appearance of metastases .", "label": "", "metadata": {}, "score": "70.54965"}
{"text": "Currently no systemic therapy has proven efficacy in delaying the appearance of metastatic disease or improving survival after biochemical relapse ( PSA failure ) .LHRH agonists are the most widely used agents in this setting .", "label": "", "metadata": {}, "score": "70.73442"}
{"text": "Cell viability was measured by XTT assay .Apoptosis was assessed through DNA fragmentation analysis and caspase 3/7 assay .mRNA and protein levels of SSTR2 and SSTR5 were evaluated by qRT - PCR and western blot analysis , respectively .", "label": "", "metadata": {}, "score": "70.8582"}
{"text": "These results indicate that this combination treatment is a significant inducer of apoptosis in a synergistic manner in breast and prostate cancer cells .This strong synergism helps to lower the dose of DTX in both types of cancers , thus letting DTX to be used for longer periods by delaying resistance development and lesser side effects .", "label": "", "metadata": {}, "score": "70.86388"}
{"text": "9810 , pp .39 - 46 , 2012 .View at Publisher \u00b7 View at Google Scholar .L. G. Presta , H. Chen , S. J. O'Connor et al . , \" Humanization of an anti - vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders , \" Cancer Research , vol .", "label": "", "metadata": {}, "score": "70.932816"}
{"text": "Finally , the comorbidities were assessed at enrollment in the study and therefore may not perfectly match those present at the time of PSA failure ; however , the fact that the ACE-27 score was significantly associated with the risk of all - cause mortality on multivariate analysis is reassuring .", "label": "", "metadata": {}, "score": "70.97237"}
{"text": "To assess the efficacy of aflibercept compared to placebo on other parameters such prostate - specific antigen ( PSA ) level , cancer related pain , progression free survival ( PFS ) , tumor - based and skeletal events and health - related quality of life ( HRQL ) ; .", "label": "", "metadata": {}, "score": "70.99931"}
{"text": "The patients included 97 women with a history of breast cancer and 66 men with prostate cancer who had undergone androgen - deprivation therapy .All patients had experienced bothersome hot flashes ( median number per day at base line , 6.1 for the women and 8.4 for the men ) .", "label": "", "metadata": {}, "score": "71.000305"}
{"text": "4 , pp .944 - 952 , 2003 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .C. R. Pound , A. W. Partin , M. A. Eisenberger , D. W. Chan , J. D. Pearson , and P. C. Walsh , \" Natural history of progression after PSA elevation following radical prostatectomy , \" The Journal of the American Medical Association , vol .", "label": "", "metadata": {}, "score": "71.02313"}
{"text": "PubMed View Article .Kucway R , Vicini F , Huang R , Stromberg J , Gonzalez J , Martinez A : Prostate volume reduction with androgen deprivation therapy before interstitial brachytherapy .", "label": "", "metadata": {}, "score": "71.08667"}
{"text": "Kaplan - Meier analysis was used to determine biochemical recurrence , disease specific and overall survival .Comparisons between groups were made using the log - rank test .", "label": "", "metadata": {}, "score": "71.24894"}
{"text": "Moreover , the clinical significance of this change is uncertain , and the prolongation of PSA doubling time has not been clearly associated with better clinical outcomes in nonmetastatic CRPC patients .", "label": "", "metadata": {}, "score": "71.52617"}
{"text": "23 - 27 , 2008 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .S. Loeb , K. A. Roehl , D. P. Viprakasit , and W. J. Catalona , \" Long - term rates of undetectable PSA with initial observation and delayed salvage radiotherapy after radical prostatectomy , \" European Urology , vol .", "label": "", "metadata": {}, "score": "71.54195"}
{"text": "Patients were observed for 5 weeks ( including a baseline week in which patients continued on their current antidepressant without gabapentin ) during which time they completed validated daily hot flash diaries .", "label": "", "metadata": {}, "score": "71.65977"}
{"text": "P. A. Kupelian , J. Katcher , H. S. Levin , and E. A. Klein , \" Stage T1 - 2 prostate cancer : a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy , \" International Journal of Radiation Oncology Biology Physics , vol .", "label": "", "metadata": {}, "score": "71.66325"}
{"text": "Treatment .Bevacizumab monotherapy was administered on an outpatient basis at a dose of 10 mg / kg intravenously every 14 days .The treatment was continued until disease progression , intolerable toxicities , or patient withdrawal from the study .", "label": "", "metadata": {}, "score": "71.887985"}
{"text": "5 , pp .1043 - 1052 , 1997 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . F. Pinto , T. Prayer - Galetti , M. Gardiman et al . , \" Clinical and pathological characteristics of patients presenting with biochemical progression after radical retropubic prostatectomy for pathologically organ - confined prostate cancer , \" Urologia Internationalis , vol .", "label": "", "metadata": {}, "score": "71.9108"}
{"text": "Figure 1 : One minus Kaplan Meier estimates of all - cause mortality following PSA failure for subgroups based on the median age at failure ( 76.6 years ) and presence or absence of ACE-27 defined moderate to severe comorbidity ( CM ) .", "label": "", "metadata": {}, "score": "72.063324"}
{"text": "Discussion .Angiogenesis is one of the key mechanisms of tumor growth and survival .Increased vascular density has been observed in prostate cancer versus that noted in normal prostate tissue [ 16 ] .", "label": "", "metadata": {}, "score": "72.08206"}
{"text": "463 - 469 , 2004 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .S. J. Freedland , E. B. Humphreys , L. A. Mangold et al . , \" Risk of prostate cancer - specific mortality following biochemical recurrence after radical prostatectomy , \" Journal of the American Medical Association , vol .", "label": "", "metadata": {}, "score": "72.45924"}
{"text": "5 , pp .1175 - 1184 , 2007 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .S. J. Buskirk , T. M. Pisansky , S. E. Schild et al . , \" Salvage radiotherapy for isolated prostate specific antigen increase after radical prostatectomy : evaluation of prognostic factors and creation of a prognostic scoring system , \" Journal of Urology , vol .", "label": "", "metadata": {}, "score": "72.52093"}
{"text": "11 , pp .1325 - 1332 , 2004 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .M. S. Anscher , R. Clough , and R. Dodge , \" Radiotherapy for a rising prostate - specific antigen after radical prostatectomy : the first 10 years , \" International Journal of Radiation Oncology Biology Physics , vol .", "label": "", "metadata": {}, "score": "72.5246"}
{"text": "PubMed View Article .Roach M III , Hanks G , Thames H , Schellhammer P , Shipley WU , Sokol GH , Sandler H : Defining biochemical failure follwing radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer : recommendations of the RTOG - ASTRO Phoenix consensus conference .", "label": "", "metadata": {}, "score": "72.53529"}
{"text": "1534 - 1540 , 2012 .View at Google Scholar .J. B. Nelson , W. Love , J. L. Chin et al . , \" Phase 3 , randomized , controlled trial of atrasentan in patients with nonmetastatic , hormone - refractory prostate cancer , \" Cancer , vol .", "label": "", "metadata": {}, "score": "72.58334"}
{"text": "A recently reported phase III study showed that denosumab , a RANKL monoclonal antibody , delayed time to bone metastasis by 3.7 months when compared to placebo in nonmetastatic CRPC patients ; however the impact on morbidity or overall survival is unknown [ 9 ] .", "label": "", "metadata": {}, "score": "72.68176"}
{"text": "Materials and methods : We retrospectively evaluated mCRC patients aged 70 or older with an Eastern Cooperative Oncology Group performance score of 2 .They had no prior treatment and underwent first - line single - agent capecitabine or other monotherapies until disease progression or unacceptable toxicity .", "label": "", "metadata": {}, "score": "72.690895"}
{"text": "Although treatment with estrogens in women and androgens in men can attenuate these symptoms , these hormones may be contraindicated in women with breast cancer and in men with prostate cancer .", "label": "", "metadata": {}, "score": "72.70709"}
{"text": "PSA failure ( biochemical failure ) was defined according to the RTOG - ASTRO Phoenix consensus [ 17 ] : ( 1 ) a rise by 2 ng / ml or more above the nadir PSA ; ( 2 ) the date of failure determined \" at call \" ( not backdated ) .", "label": "", "metadata": {}, "score": "72.80909"}
{"text": "4 , pp .1127 - 1133 , 2003 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . A. V. D'Amico , M.-H. Chen , A. A. Renshaw , M. Loffredo , and P. W. Kantoff , \" Androgen suppression and radiation vs radiation alone for prostate cancer : a randomized trial , \" Journal of the American Medical Association , vol .", "label": "", "metadata": {}, "score": "72.81801"}
{"text": "Combination treatment increased both SSTR2 and SSTR5 mRNA and protein levels in DU-145 cells .The data suggest that this combination therapy may be a good candidate for patients with advanced metastatic PCa do not respond to androgen deprivation .", "label": "", "metadata": {}, "score": "72.898476"}
{"text": "Patients who died were censored at the time of death according to their status at that time .Disease specific mortality was defined as death from prostate cancer ( patients who died with evidence of disease recurrence without an independent diagnosis responsible for the patient 's death ) .", "label": "", "metadata": {}, "score": "72.95815"}
{"text": "The XTT cell viability assay was used to determine cytotoxicity .Apoptosis was evaluated by Cell Death Detection ELISA(Plus ) Kit .The expression levels of apoptotic proteins were assessed by human apoptosis antibody array .", "label": "", "metadata": {}, "score": "73.28546"}
{"text": "Designing good clinical studies for nonmetastatic prostate cancer is a dire need , and meeting the challenge of clinical trial accrual in this asymptomatic but threatened patient population should remain a priority .", "label": "", "metadata": {}, "score": "73.34587"}
{"text": "PubMed Central PubMed View Article .Pond GR , Armstrong AJ , Wood BA , Leopold L , Galsky MD , Sonpavde G : Ability of C - reactive protein to complement multiple prognostic classifiers in men with metastatic castration resistant prostate cancer receiving docetaxel - based chemotherapy .", "label": "", "metadata": {}, "score": "73.37975"}
{"text": "This study was approved by the institutional review board of Jichi Medical University .The clinical trial was registered in the University Hospital Medical Information Network Clinical Trials Registry ( UMIN - CTR ) UMIN000011969 .", "label": "", "metadata": {}, "score": "73.51814"}
{"text": "Pinkawa M : External beam radiotherapy for prostate cancer .Panminerva Med 2010 , 52 : 195 - 207 .PubMed .Pinkawa M , Piroth DM , Holy R , Fischedick K , Schaar S , Borchers H , Heidenreich A , Eble MJ : Prostate - specific antigen kinetics following external - beam radiotherapy and temporary ( Ir-192 ) or permanent ( I-125 ) brachytherapy for prostate cancer .", "label": "", "metadata": {}, "score": "73.558815"}
{"text": "43 - 47 , 2006 .View at Google Scholar \u00b7 View at Scopus . A. J. Stephenson , P. T. Scardino , M. W. Kattan et al . , \" Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy , \" Journal of Clinical Oncology , vol .", "label": "", "metadata": {}, "score": "73.586044"}
{"text": "369 - 375 , 2000 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .J. R. Bernard , S. J. Buskirk , M. G. Heckman et al . , \" Salvage radiotherapy for rising prostate - specific antigen levels after radical prostatectomy for prostate cancer : dose - response analysis , \" International Journal of Radiation Oncology Biology Physics , vol .", "label": "", "metadata": {}, "score": "73.59828"}
{"text": "Although survival rate of early - stage PCa is high , treatment options are very limited for recurrent disease .In this study , the possible synergistic cytotoxic and apoptotic effect of octreotide in combination with AT-101 was investigated in DU-145 hormone and drug refractory prostate cancer cell line .", "label": "", "metadata": {}, "score": "73.65961"}
{"text": "4 , pp .235 - 242 , 2011 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .W. H. Pinover , E. M. Horwitz , A. L. Hanlon , R. G. Uzzo , and G. E. Hanks , \" Validation of a treatment policy for patients with prostate specific antigen failure after three - dimensional conformal prostate radiation therapy , \" Cancer , vol .", "label": "", "metadata": {}, "score": "73.74643"}
{"text": "Prostate cancer Radiotherapy Brachytherapy Ir-192 Prostate - specific antigen Hormone therapy .Background .External beam radiotherapy ( EBRT ) and temporary interstitial brachytherapy ( HDR - BT ) are all well established radiotherapy ( RT ) techniques for a curative treatment of localized prostate cancer [ 1 - 7 ] .", "label": "", "metadata": {}, "score": "73.79593"}
{"text": "Treatment consisted of oxaliplatin 130 mg / m2 and capecitabine 1000 mg / m2 twice daily with a 3 week interval , until unacceptable toxicity or disease progression .", "label": "", "metadata": {}, "score": "73.90893"}
{"text": "The median TTP and OS were 5.7 months ( 95 % CI : 5.0 - 6.3 ) and 10.2 months ( 95 % CI : 8.6 - 11.8 ) , respectively .", "label": "", "metadata": {}, "score": "73.99361"}
{"text": "PubMed View Article .BJU Int 2012 , 109 ( Suppl.1 ) : 22 - 29 .PubMed View Article .Gill S , Thomas J , Fox C , Kron T , Rolfo A , Leahy M , Chander S , Williams S , Tai KH , Duchesne GM , Foroudi F : Acute toxicity in prostate cancer patients treated with and without image - guided radiotherapy .", "label": "", "metadata": {}, "score": "74.0663"}
{"text": "In summary , bevacizumab monotherapy had only a modest impact at best , on PSA doubling time and no clinical impact in nonmetastatic CRPC patients .", "label": "", "metadata": {}, "score": "74.11084"}
{"text": "Bevacizumab was withheld at least 2 weeks prior to any minor procedure ( e.g. , dental extraction , superficial skin lipoma removal ) and at least 4 weeks prior to any major surgical procedure .", "label": "", "metadata": {}, "score": "74.31053"}
{"text": "The additional challenge in this population is that patients are asymptomatic and subjecting them to potentially toxic therapies requires careful consideration .Bevacizumab is generally considered a well - tolerated biologic agent , but it can potentially cause significant side effects , and 4 out of 15 patients in our study developed grade 3 or higher adverse events .", "label": "", "metadata": {}, "score": "74.47905"}
{"text": "956 - 962 , 2009 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .T. H. Van Der Kwast , M. Bolla , H. Van Poppel et al . , \" Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy : EORTC 22911 , \" Journal of Clinical Oncology , vol .", "label": "", "metadata": {}, "score": "74.48492"}
{"text": "PubMed View Article .Hoskin PJ , Rojas AM , Bownes PJ , Lowe GJ , Ostler PJ , Bryant L : Randomised trial of external beam radiotherapy alone or combined with high - dose - rate brachytherapy boost for localised prostate cancer .", "label": "", "metadata": {}, "score": "74.68083"}
{"text": "From very recent retrospective reports , it became obvious that total doses of more than 66 Gy can be used safely when modern techniques are available [ 26 , 27 , 29 , 36 ] .", "label": "", "metadata": {}, "score": "74.69777"}
{"text": "9485 , pp .572 - 578 , 2005 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .I. M. Thompson Jr. , C. M. Tangen , J. Paradelo et al . , \" Adjuvant radiotherapy for pathologically advanced prostate cancer : a randomized clinical trial , \" Journal of the American Medical Association , vol .", "label": "", "metadata": {}, "score": "74.71413"}
{"text": "Based on these findings , 1st - line capecitabine should be considered in slowly progressing disease , offering an active , well - tolerated oral treatment with minimal toxicity and no alopecia .", "label": "", "metadata": {}, "score": "74.77548"}
{"text": "Castration - resistant prostate cancer ( CRPC ) patients have poor prognoses .Although many treatment options have been developed , truly effective ones remain limited [ 1 - 6 ] .", "label": "", "metadata": {}, "score": "75.11827"}
{"text": "5 , pp .1089 - 1096 , 2008 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . F. Francini , A. Pascucci , E. Francini , et al . , \" Bevacizumab and weekly docetaxel in patients with metastatic castrate - resistant prostate cancer previously exposed to docetaxel , \" Prostate Cancer , vol .", "label": "", "metadata": {}, "score": "75.59457"}
{"text": "32 - 39 , 2012 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .M. K. Buyyounouski , A. L. Hanlon , E. M. Horwitz , and A. Pollack , \" Interval to biochemical failure highly prognostic for distant metastasis and prostate cancer - specific mortality after radiotherapy , \" International Journal of Radiation Oncology Biology Physics , vol .", "label": "", "metadata": {}, "score": "75.59886"}
{"text": "Introduction .In select cases , where men experience both long intervals to PSA recurrence and slow PSA doubling times , a PSA rise reflects a local - only failure and salvage local therapy is an option [ 3 ] .", "label": "", "metadata": {}, "score": "75.601715"}
{"text": "The French Groupe d ' \u00c9tude des Tumeurs Uro - G\u00e9nitales ( GETUG ) has activated the GETUG-17 trial ( NCT00667069 ) comparing adjuvant versus salvage RT combined with 6 months of hormonal therapy .", "label": "", "metadata": {}, "score": "75.63277"}
{"text": "5 , pp .1411 - 1417 , 2007 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .C. Catton , M. Gospodarowicz , P. Warde et al . , \" Adjuvant and salvage radiation therapy after radical prostatectomy for adenocarcinoma of the prostate , \" Radiotherapy and Oncology , vol .", "label": "", "metadata": {}, "score": "75.66178"}
{"text": "Partial regressions were seen in 3 of 15 ( 20 % ) measurable disease patients , and objective regressions were seen in 3 of 14 ( 21 % ) evaluable / nonmeasurable disease patients .", "label": "", "metadata": {}, "score": "75.78098"}
{"text": "Chemotherapy with MACC , in combination with thoracic radiotherapy , did not result in significant survival advantage compared with radiation alone ( P greater than 0.2 ) in patients with medically inoperable or unresectable stage III non - small cell lung cancer .", "label": "", "metadata": {}, "score": "75.916214"}
{"text": "Abbreviations : PSA , prostate - specific antigen ; PCa , prostate cancer ; DTX , docetaxel ; PSADT , prostate - specific antigen doubling time ; ECOG , Eastern Cooperative Oncology Group ; ALP , alkaline phosphatase .", "label": "", "metadata": {}, "score": "75.99745"}
{"text": "Adjuvant radiotherapy is defined as treatment given directly after surgery in the presence of risk factors ( R1 resection , pT3 ) before biochemical relapse occurs .", "label": "", "metadata": {}, "score": "76.21189"}
{"text": "17 , pp .1591 - 1597 , 1999 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .S. J. Freedland , E. B. Humphreys , L. A. Mangold et al . , \" Risk of prostate cancer - specific mortality following biochemical recurrence after radical prostatectomy , \" The Journal of the American Medical Association , vol .", "label": "", "metadata": {}, "score": "76.31569"}
{"text": "Nonmetastatic CRPC remains a challenging disease .So far , several agents have been tested without successful outcomes [ 20 , 25 , 26 ] .", "label": "", "metadata": {}, "score": "76.33673"}
{"text": "205 - 213 , 2008 .View at Publisher \u00b7 View at Google Scholar .L. V. Do , T. M. Do , R. Smith , and R. G. Parker , \" Postoperative radiotherapy for carcinoma of the prostate : impact on both local control and distant disease - free survival , \" American Journal of Clinical Oncology , vol .", "label": "", "metadata": {}, "score": "76.365906"}
{"text": "Febrile neutropenia was not observed and there were no toxicity - associated deaths .Conclusions : Capecitabine is a safe chemotherapeutic agent with moderate activity for first - line treatment of older metastatic colorectal cancer patients with limited performance status .", "label": "", "metadata": {}, "score": "76.43941"}
{"text": "Methods : We retrospectively reviewed the medical records of 395 mCRC patients referred to our clinic .The study included patients who received 5-fluorouracil ( 5-FU)- , irinotecan- or oxaliplatin - based chemotherapy and at least 3 cycles of bevacizumab and 4 weeks of cetuximab sequentially in various combinations .", "label": "", "metadata": {}, "score": "76.48581"}
{"text": "In the absence of PSA progression or death , the participant was censored at the the date of last assessment without evidence of progression or the study cut - off date , whichever was earlier .", "label": "", "metadata": {}, "score": "76.60075"}
{"text": "In the absence of disease progression , the participant was censored at the the date of last assessment without evidence of progression or the study cut - off date , whichever was earlier .", "label": "", "metadata": {}, "score": "76.72817"}
{"text": "However , genes of the angiogenic pathway and angiogenic biomarkers vary substantially , thereby causing interindividual differences that complicate the identification of predictors for anti - vascular endothelial growth factor drugs like bevacizumab .", "label": "", "metadata": {}, "score": "76.92867"}
{"text": "A multivariate analysis was performed to clarify the relationship between the ARC and major patient characteristics .Results .Seventy - eight CRPC patients met the inclusion criteria .", "label": "", "metadata": {}, "score": "76.97646"}
{"text": "20 , pp .4593 - 4599 , 1997 .View at Google Scholar \u00b7 View at Scopus .G. di Lorenzo , W. D. Figg , S. D. Fossa et al . , \" Combination of bevacizumab and docetaxel in docetaxel - pretreated hormone - refractory prostate cancer : a phase 2 study , \" European Urology , vol .", "label": "", "metadata": {}, "score": "76.992096"}
{"text": "4 , pp .1009 - 1016 , 2009 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . D. Neuhof , T. Hentschel , M. Bischof , G. Sroka - Perez , M. Hohenfellner , and J. Debus , \" Long - term results and predictive factors of three - dimensional conformal salvage radiotherapy for biochemical relapse after prostatectomy , \" International Journal of Radiation Oncology Biology Physics , vol .", "label": "", "metadata": {}, "score": "77.13074"}
{"text": "METHODS Patients with progressive AIPC received 90 mg / m2 paclitaxel by 1-hour intravenous infusion weekly for 3 weeks , followed by a 1-week treatment rest .", "label": "", "metadata": {}, "score": "77.242966"}
{"text": "PubMed View Article .Oudard S , Banu E , Medioni J , Scotte F , Banu A , Levy E , Wasserman J , Kacso G , Andrieu JM : What is the real impact of bone pain on survival in patients with metastatic hormone - refractory prostate cancer treated with docetaxel ?", "label": "", "metadata": {}, "score": "77.244995"}
{"text": "269- 276 , 2002 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .T. Wiegel , G. Lohm , D. Bottke et al . , \" Achieving an undetectable PSA after radiotherapy for biochemical progression after radical prostatectomy is an independent predictor of biochemical outcome - results of a retrospective study , \" International Journal of Radiation Oncology Biology Physics , vol .", "label": "", "metadata": {}, "score": "77.31694"}
{"text": "14 , pp .4526 - 4531 , 2008 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .M. Bilusic , J. L. Gulley , C. Heery , et al . , \" A randomized phase II study of flutamide with or without PSA - TRICOM in nonmetastatic castration - resistant prostate cancer ( CRPC ) , \" ASCO Meeting Abstracts , vol .", "label": "", "metadata": {}, "score": "77.32948"}
{"text": "The horizontal lines in the boxes represent median PSA and \" + \" represents mean value .The numbers above the vertical lines are the number of patients .", "label": "", "metadata": {}, "score": "77.38402"}
{"text": "One of the mechanisms of action of bevacizumab is through its effects on stroma without direct cytotoxic effect [ 21 ] .A perfect example of a similar phenomenon is that , in colon cancer , the addition of bevacizumab to cytotoxic chemotherapy improved overall survival in metastatic disease , but not in the adjuvant setting [ 22 , 23 ] .", "label": "", "metadata": {}, "score": "77.39537"}
{"text": "Possible survival benefit was observed in those who received initial immunotherapy , and a larger scale study is currently ongoing [ 27 ] .Denosumab is a monoclonal antibody against RANKL and inhibits the osteoclast activity .", "label": "", "metadata": {}, "score": "77.60713"}
{"text": "5 , pp .1405 - 1418 , 2009 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .C. R. King and D. S. Kapp , \" Radiotherapy after prostatectomy : is the evidence for dose escalation out there ? \"", "label": "", "metadata": {}, "score": "77.67302"}
{"text": "This study has been designed by KN and TM .The clinical database of the patients have been acquired by KN , KK , TK , SN , AN , SK , MK and TM .", "label": "", "metadata": {}, "score": "77.75198"}
{"text": "PubMed View Article .Viani GA , Stefano EJ , Alfonso SL : Higher - than - conventional radiation doses in localized prostate cancer treatment .", "label": "", "metadata": {}, "score": "77.820435"}
{"text": "There are several possible explanations for this outcome .First of all , our patients had multiple poor prognostic features .Secondly , our patient population had a higher proportion of patients with locally advanced disease stage at diagnosis , which explains why most patients had received radiation therapy as the primary local therapy .", "label": "", "metadata": {}, "score": "77.92474"}
{"text": "Official Title : .A Multicenter , Randomized , Double Blind Study Comparing the Efficacy and Safety of Aflibercept Versus Placebo Administered Every 3 Weeks in Patients Treated With Docetaxel/ Prednisone for Metastatic Androgen - independent Prostate Cancer .", "label": "", "metadata": {}, "score": "77.9803"}
{"text": "6973 , p. 170 , 1995 .View at Google Scholar \u00b7 View at Scopus . E. M. Messing , J. Manola , J. Yao et al . , \" Immediate versus deferred androgen deprivation treatment in patients with node - positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy , \" The Lancet Oncology , vol .", "label": "", "metadata": {}, "score": "78.048485"}
{"text": "Patients sometimes receive HT until PSA levels rise after an initial PSA nadir .These patients were in focus of this analysis .Patients after EBRT alone and EBRT with an additional HDR - BT boost have been included in this evaluation to verify the results independently in two separate patient groups with different radiotherapy concepts .", "label": "", "metadata": {}, "score": "78.05618"}
{"text": "At our institution , patients with metastatic and/or first treatment - refractory prostate cancer ( PCa ) are treated with androgen deprivation therapy ( ADT ) .", "label": "", "metadata": {}, "score": "78.2433"}
{"text": "16 , pp .2225 - 2229 , 2007 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .M. N. Simmons , A. J. Stephenson , and E. A. Klein , \" Natural history of biochemical recurrence after radical prostatectomy : risk assessment for secondary therapy , \" European Urology , vol .", "label": "", "metadata": {}, "score": "78.66168"}
{"text": "All analyses were performed using SAS software ( version 9.3 ; SAS Institute , Cary , NC ) .Results .Patient Characteristics Stratified by Survival Status .", "label": "", "metadata": {}, "score": "78.8208"}
{"text": "There was no treatment - related mortality .Conclusion .Bevacizumab therapy had minimal impact on the disease course of nonmetastatic CRPC , and investigation of novel strategies is needed .", "label": "", "metadata": {}, "score": "78.93821"}
{"text": "Please refer to this study by its ClinicalTrials.gov identifier : NCT00519285 .Neoplasm Metastasis Neoplasms Prostatic Neoplasms Genital Diseases , Male Genital Neoplasms , Male Neoplasms by Site Neoplastic Processes Pathologic Processes Prostatic Diseases Urogenital Neoplasms Docetaxel Methylprednisolone Methylprednisolone Hemisuccinate Methylprednisolone acetate Prednisolone .", "label": "", "metadata": {}, "score": "78.98169"}
{"text": "View at Publisher \u00b7 View at Google Scholar .R. W. Ross , M. D. Galsky , P. Febbo , et al . , \" Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high - risk localized prostate cancer , \" Cancer .", "label": "", "metadata": {}, "score": "79.02125"}
{"text": "21 , no . 3 , pp .483 - 489 , 2003 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . A. J. Stephenson , S. F. Shariat , M. J. Zelefsky et al . , \" Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy , \" Journal of the American Medical Association , vol .", "label": "", "metadata": {}, "score": "79.17718"}
{"text": "735 - 740 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .G. De Meerleer , V. Fonteyne , S. Meersschout et al . , \" Salvage intensity - modulated radiotherapy for rising PSA after radical prostatectomy , \" Radiotherapy and Oncology , vol .", "label": "", "metadata": {}, "score": "79.292725"}
{"text": "Toxicity .Fourteen patients had discontinued bevacizumab by the time of this analysis .Thirteen patients discontinued the therapy due to disease progression , and one patient discontinued bevacizumab due to occurrence of grade 4 pulmonary embolism , which occurred during the third cycle of treatment .", "label": "", "metadata": {}, "score": "79.34833"}
{"text": "The aim of this study was to investigate the prognostic factors of adjuvant chemotherapy in Turkish patients with stage II colon cancer .Methods : A total of 554 stage II colon cancer patients were retrospectively enrolled in the study .", "label": "", "metadata": {}, "score": "79.58093"}
{"text": "4 , pp .966 - 974 , 2009 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .M. Feng , A. L. Hanlon , T. M. Pisansky et al . , \" Predictive factors for late genitourinary and gastrointestinal toxicity in patients with prostate cancer treated with adjuvant or salvage radiotherapy , \" International Journal of Radiation Oncology Biology Physics , vol .", "label": "", "metadata": {}, "score": "79.70643"}
{"text": "Overall survival curves according to Armstrong risk classification [ 10 ] .Subgroup analysis .A multivariate analysis was performed to clarify the relationship between the ARC and the major patient characteristics that are often evaluated in clinical practice .", "label": "", "metadata": {}, "score": "79.794075"}
{"text": "289 - 295 , 2008 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus Abstract .Background .Castration - resistant prostate cancer ( CRPC ) patients have poor prognoses , and docetaxel ( DTX ) is among the few treatment options .", "label": "", "metadata": {}, "score": "80.12829"}
{"text": "Previous agents used included capecitabine , anthracycline , and vinorelbine in 54 , 40 and 21 % of cases , respectively .The median number of docetaxel cycles was 6 ( range : 1 - 18 ) .", "label": "", "metadata": {}, "score": "80.2614"}
{"text": "A bone scan and abdominal computed tomography scan was required to exclude lymph node or skeletal metastases for high risk patients at the time of the initial diagnosis .", "label": "", "metadata": {}, "score": "80.41512"}
{"text": "Statistical analysis .Statistical analysis was performed using the SPSS 19.0 ( SPSS , Chicago , Ill ) , software .Contingency table analysis with the chi - square test was performed to compare treatment groups with respect to categorical variables .", "label": "", "metadata": {}, "score": "80.5399"}
{"text": "There was no difference in median TTP after subsequent docetaxel in subgroup analyses .This retrospective analysis supports the pragmatic strategy to retreat patients with MBC with docetaxel when this drug has shown previous activity and was stopped for other causes than progression .", "label": "", "metadata": {}, "score": "80.78192"}
{"text": "Three major groups of variables became apparent as providing strong prognostic information .These included the following : ( 1 ) a physician 's assessment of performance status ( PS ) ; ( 2 ) a patient 's assessment of their own PS ; and ( 3 ) a nutritional factor such as appetite , caloric intake , or overall food intake .", "label": "", "metadata": {}, "score": "80.89703"}
{"text": "PubMed View Article .Int J Radiat Oncol Biol Phys 2009 , 73 : 327 - 333 .PubMed View Article .Sathya JR , Davis IR , Julian JA , Guo Q , Daya D , Dayes IS , Lukka HR , Levine M : Randomized trial comparing Iridium implant plus external - beam radiotherapy with external - beam radiotherapy alone in node - negative locally advanced cancer of the prostate .", "label": "", "metadata": {}, "score": "80.96732"}
{"text": "Kantoff PW , Higano CS , Shore ND , Berger ER , Small EJ , Penson DF , Redfern CH , Ferrari AC , Dreicer R , Sims RB , Xu Y , Frohlich MW , Schellhammer PF , Impact Study Investigators : Sipuleucel - T immunotherapy for castration - resistant prostate cancer .", "label": "", "metadata": {}, "score": "81.07702"}
{"text": "15 , pp .2035 - 2041 , 2007 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .M. Bolla , H. Van Poppel , L. Collette et al . , \" Postoperative radiotherapy after radical prostatectomy : a randomised controlled trial ( EORTC trial 22911 ) , \" The Lancet , vol .", "label": "", "metadata": {}, "score": "81.13847"}
{"text": "Conclusions : Our result suggests that the combination of capecitabine and oxaliplatin was tolerated with manageable toxicity and showed encouraging activity as second - line treatment of advanced or metastatic pancreatic cancer patients with ECOG performance status 0 - 2 .", "label": "", "metadata": {}, "score": "81.282265"}
{"text": "Thus , the ARC tends to classify many CRPC patients with low PSA levels as good - risk .At the comparison of the prognoses and/or treatment responses of CRPC patients , the ARC would ensure more accurate outcomes while considering the above - mentioned ARC characteristics .", "label": "", "metadata": {}, "score": "81.283905"}
{"text": "However , early screening of brain metastases in patients with lung metastasis may improve survival outcomes with new treatment modalities .[ Show abstract ] [ Hide abstract ] ABSTRACT : The identification of clinical , biochemical and molecular markers to predict or monitor the efficacy of bevacizumab represents a major point in the treatment of patients with metastatic colorectal cancer .", "label": "", "metadata": {}, "score": "81.29036"}
{"text": "However , few reports have externally validated ARC in CRPC patients who were administered DTX .Under external validation , risk classifications and nomograms might be found to have positive [ 12 ] or negative [ 13 ] effects and , sometimes , to clarify characteristics at the time of clinical use [ 14 ] .", "label": "", "metadata": {}, "score": "81.34927"}
{"text": "[ Show abstract ] [ Hide abstract ] ABSTRACT : To compare the survival of patients with medically inoperable or unresectable stage III non - small cell lung cancer treated with thoracic radiotherapy alone or in combination with chemotherapy .", "label": "", "metadata": {}, "score": "81.934006"}
{"text": "Primary objective was to demonstrate overall survival improvement with aflibercept compared to placebo in patients receiving docetaxel / prednisone for metastatic androgen - independent prostate cancer ( MAIPC ) .", "label": "", "metadata": {}, "score": "82.04934"}
{"text": "121 - 127 , 2007 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .G. A. Viani , E. J. Stefano , and S. L. Afonso , \" Higher - than - conventional radiation doses in localized prostate cancer treatment : a meta - analysis of randomized , controlled trials , \" International Journal of Radiation Oncology Biology Physics , vol .", "label": "", "metadata": {}, "score": "82.07932"}
{"text": "Predictions and classifications of CRPC patients ' clinical outcomes and prognoses for the effective use of the limited treatment options offer prolonged survival to the patients .", "label": "", "metadata": {}, "score": "82.109604"}
{"text": "1868 - 1876 , 2006 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . S. L. Faria , S. Mahmud , L. Souhami et al . , \" No immediate treatment after biochemical failure in patients with prostate cancer treated by external beam radiotherapy , \" Urology , vol .", "label": "", "metadata": {}, "score": "82.23216"}
{"text": "5-Fluorouracil , as administered in this protocol , had modest antitumor activity in cisplatin - refractory ovarian carcinoma of short duration and minimal toxicity .", "label": "", "metadata": {}, "score": "82.289566"}
{"text": "Pilepich MV , Winter K , Lawton CA , Krisch RE , Wolkov HB , Movsas B , Hug EB , Asbell SO , Grignon D : Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma - long - term results of phase III RTOG 85 - 31 .", "label": "", "metadata": {}, "score": "82.45799"}
{"text": "The RADICALS ( radiotherapy and androgen deprivation in combination after local surgery ) trial ( NCT00541047 ) conducted by the Medical Research Council ( UK ) and the National Cancer Institute of Canada Clinical trials Group aims to recruit 4000 patients ; primary endpoint is 10-year prostate - cancer - specific survival .", "label": "", "metadata": {}, "score": "82.70357"}
{"text": "Methods .CRPC patients who received 2 or more DTX cycles were selected for this study .Patients were classified into good- , intermediate- , and poor - risk groups according to the ARC .", "label": "", "metadata": {}, "score": "82.70735"}
{"text": "N Engl J Med 2011 , 364 : 1995 - 2005 .PubMed Central PubMed View Article .N Engl J Med 2012 , 367 : 1187 - 1197 .", "label": "", "metadata": {}, "score": "82.7617"}
{"text": "View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .C. R. King and M. T. Spiotto , \" Improved outcomes with higher doses for salvage radiotherapy after prostatectomy , \" International Journal of Radiation Oncology Biology Physics , vol .", "label": "", "metadata": {}, "score": "82.83816"}
{"text": "In the absence of event , the participant was censored at the the date of last assessment without evidence of pain progression or the study cut - off date , whichever was earlier .", "label": "", "metadata": {}, "score": "83.02005"}
{"text": "5 , pp .1417 - 1423 , 2007 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .G. P. Swanson , M. A. Hussey , C. M. Tangen et al . , \" Predominant treatment failure in postprostatectomy patients is local : analysis of patterns of treatment failure in SWOG 8794 , \" Journal of Clinical Oncology , vol .", "label": "", "metadata": {}, "score": "83.02094"}
{"text": "The definition of \" nonmetastatic \" prostate cancer continues to change with wider application of more sophisticated imaging techniques such as magnetic resonance imaging ( MRI ) and positron emission tomography ( PET ) scan [ 28 ] .", "label": "", "metadata": {}, "score": "83.338715"}
{"text": "23 , pp .2760 - 2769 , 2008 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .R. Choo , G. Hruby , J. Hong et al . , \" ( IN)-efficacy of salvage radiotherapy for rising PSA or clinically isolated local recurrence after radical prostatectomy , \" International Journal of Radiation Oncology Biology Physics , vol .", "label": "", "metadata": {}, "score": "83.43206"}
{"text": "4 , pp .433 - 439 , 2005 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .\" Immediate versus deferred treatment for advanced prostatic cancer : initial results of the Medical Research Council trial .", "label": "", "metadata": {}, "score": "83.48514"}
{"text": "Multi - institutional cooperative oncology group .A total of 121 patients were enrolled in the study , of whom 7 ( 5.8 % ) were ineligible .", "label": "", "metadata": {}, "score": "83.59215"}
{"text": "The c - index for OS was 0.60 , indicating that the ARC had a modest discriminatory ability in the validation group .A multivariate analysis revealed that the ARC was an independent prognostic factor .", "label": "", "metadata": {}, "score": "83.75885"}
{"text": "Armstrong risk classification assessment .Waterfall plots of PSA response according to each ARC risk group are shown in Figure 1 .Waterfall plots of prostate - specific antigen ( PSA ) responses according to total ( a ) , good-(b ) , intermediate-(c ) , and poor-(d ) risk group of Armstrong risk classification .", "label": "", "metadata": {}, "score": "83.835526"}
{"text": "Figure 4 : The Kaplan - Meier plot of the censored time to new metastasis distribution .Only two patients have died to date ; therefore it is premature to analyze the OS data .", "label": "", "metadata": {}, "score": "83.92317"}
{"text": "The referring urologist decided about the indication for HT due to prognostic risk factors or to offer an immediate treatment before a later decision for a definitive curative method .", "label": "", "metadata": {}, "score": "83.969986"}
{"text": "Abstract .Introduction / Background .Nonmetastatic castrate resistant prostate cancer ( CRPC ) is a challenging disease state .The objective of this study was to evaluate the efficacy and tolerability of bevacizumab in nonmetastatic CRPC patients .", "label": "", "metadata": {}, "score": "83.98038"}
{"text": "24 , pp .8669 - 8673 , 2005 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .L. H. Klotz , \" PSA recurrence : definitions , PSA kinetics , and identifying patients at risk , \" The Canadian Journal of Urology , vol .", "label": "", "metadata": {}, "score": "84.06882"}
{"text": "Results .Patients .During the study period , 102 CRPC patients received DTX at our institution , among whom , 78 met the inclusion criteria .", "label": "", "metadata": {}, "score": "84.13568"}
{"text": "Bevacizumab is a fully humanized anti - VEGF monoclonal IgG 1 antibody [ 10 ] .In phase II studies , the addition of bevacizumab to docetaxel demonstrated 37 - 49 % objective response rates in patients who had been pretreated with docetaxel [ 11 , 12 ] .", "label": "", "metadata": {}, "score": "84.18724"}
{"text": "In this review we have summarized the potential candidate biomarkers that may have a role in identifying patients who benefit most from bevacizumab treatment .[ Show abstract ] [ Hide abstract ] ABSTRACT : Background : Unlike for fit elderly metastatic colorectal cancer ( mCRC ) patients , general approaches to initial treatment for the frail older mCRC patients are not clear .", "label": "", "metadata": {}, "score": "84.20331"}
{"text": "Continuous data were divided into 2 groups according to median value .A concordance index ( c - index ) was estimated as a measure of the ARC discriminatory index .", "label": "", "metadata": {}, "score": "84.20396"}
{"text": "[ Show abstract ] [ Hide abstract ] ABSTRACT : In 2005 , 224 patients received adjuvant / neoadjuvant chemotherapy for breast cancer in a single institution according to daily practices .", "label": "", "metadata": {}, "score": "84.223694"}
{"text": "First , these tumours consist of a considerable amount of preselected aggressive cells that are resistant to antiandrogen therapy and apparently simultaneously resistant to radiation .", "label": "", "metadata": {}, "score": "84.511505"}
{"text": "Possible ways to improve the applicability of results such as increasing the minimum age for inclusion and the use of CGA are proposed .[ Show abstract ] [ Hide abstract ] ABSTRACT : Primary treatment goals in less aggressive metastatic breast cancer ( MBC ) are prolonged survival , good quality of life and control of the disease and its symptoms .", "label": "", "metadata": {}, "score": "84.53847"}
{"text": "For all the other patients carrying less pronounced risk factors for tumor recurrence , it seems more reasonable to balance the superior initial quality of life and the lower risk of clinical or PSA recurrence in favour of salvage RT .", "label": "", "metadata": {}, "score": "84.753105"}
{"text": "Firstly , a review of the literature was performed identifying 39 publications about chemotherapy for MBC focusing on elderly patients and we examined patient characteristics in each of these publications .", "label": "", "metadata": {}, "score": "84.84723"}
{"text": "In the absence of SRE , the participant was censored at the last date he / she was known to be alive or the study cut - off date , whichever was earlier .", "label": "", "metadata": {}, "score": "85.06502"}
{"text": "The patients documented the frequency and severity of hot flashes in daily symptom diaries .The degree of efficacy was similar in men and women .", "label": "", "metadata": {}, "score": "85.12071"}
{"text": "Materials and Methods .Data for this paper were identified by searches of MEDLINE , Current Contents , PubMed , and references from relevant articles using medical subject headings including prostate cancer , postoperative , radiotherapy , adjuvant , and salvage .", "label": "", "metadata": {}, "score": "85.38597"}
{"text": "View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .View at Google Scholar .B. J. Trock , M. Han , S. J. Freedland et al . , \" Prostate cancer - specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy , \" Journal of the American Medical Association , vol .", "label": "", "metadata": {}, "score": "85.53024"}
{"text": "N Engl J Med 2009 , 360 : 2516 - 2527 .PubMed View Article .J Clin Oncol 2003 , 21 : 3972 - 3978 .", "label": "", "metadata": {}, "score": "85.5307"}
{"text": "Table 2 .Univariate analysis for overall survival according to each risk factor of Armstrong risk classification [ 10 ] .Patient distributions and OS curves according to the ARC risk groups are shown in Figure 2 .", "label": "", "metadata": {}, "score": "85.641754"}
{"text": "In this cross - sectional study , the medical files of colorectal cancer patients with brain metastases who were definitely diagnosed by histopatho - logically were retrospectively reviewed .", "label": "", "metadata": {}, "score": "85.90437"}
{"text": "53 , pp .457 - 481 , 1958 .View at Publisher \u00b7 View at Google Scholar .J. M. Bland and D. G. Altman , \" Multiple significance tests : the Bonferroni method , \" British Medical Journal , vol .", "label": "", "metadata": {}, "score": "85.97676"}
{"text": "However , there were no statistically significant differences in PSA response between the ARC risk groups .The CRPC patients with a history of EMP use showed significantly lower PSA response during DTX treatment than those without a history of EMP use [ 10 ] .", "label": "", "metadata": {}, "score": "86.15705"}
{"text": "We designed our study protocol which would discontinue bevacizumab upon PSA progression conforming to real practice in the USA .This may have been a flawed assessment since the impact of bevacizumab monotherapy on PSA levels is unknown .", "label": "", "metadata": {}, "score": "86.20056"}
{"text": "Cause of death was determined by the treating oncologist who followed the patient from study entry until death .This retrospective analysis of the prospectively collected study data was approved by the institute institutional review board .", "label": "", "metadata": {}, "score": "86.36304"}
{"text": "On the other hand , the natural course and life expectancy of men besides prostate cancer have to be considered , with its enormous global inequality [ 43 ] .", "label": "", "metadata": {}, "score": "86.538635"}
{"text": "EMP could be reduced to 280 mg / day according to the degree of adverse events and , if already administered before DTX initiation , continued at the same dose that was administered before DTX treatment .", "label": "", "metadata": {}, "score": "86.64664"}
{"text": "Finally , the RAVES ( radiotherapy adjuvant versus early salvage ) trial ( NCT00860652 ) has been activated by the Tasman Radiation Oncology Group ( TROG ) comparing adjuvant versus salvage RT ( 64 Gy ) without hormonal treatment .", "label": "", "metadata": {}, "score": "86.77316"}
{"text": "University Hospital Medical Information Network Clinical Trials Registry ( UMIN - CTR ) number , UMIN000011969 .Keywords .Castration - resistant prostate cancer Docetaxel Risk classification Validation study .", "label": "", "metadata": {}, "score": "86.81543"}
{"text": "Radical prostatectomy ( RP ) provides excellent cancer control in patients with localized prostate cancer .However , half of all patients present with one or more risk factors for recurrent disease including higher Gleason Score , extracapsular extension ( TNM tumor classification pT3a ) , invasion of the seminal vesicles ( pT3b ) , or positive resection margins ( R1 ) .", "label": "", "metadata": {}, "score": "87.18968"}
{"text": "2478 - 2487 , 2008 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . H. Hurwitz , L. Fehrenbacher , W. Novotny et al . , \" Bevacizumab plus irinotecan , fluorouracil , and leucovorin for metastatic colorectal cancer , \" New England Journal of Medicine , vol .", "label": "", "metadata": {}, "score": "87.24002"}
{"text": "We externally validated the ARC in CRPC patients who were administered DTX in 2 or more cycles and showed that there were statistically significant differences in OS among the ARC risk groups .", "label": "", "metadata": {}, "score": "87.2505"}
{"text": "This means that CRPC patients who are classified into good- and intermediate - risk groups are recommended for aggressive DTX administration , because these patients would be expected to experience prolonged OS in response to DTX .", "label": "", "metadata": {}, "score": "87.58266"}
{"text": "Int J Radiat Oncol Biol Phys 2010 , 76 : 23 - 30 .PubMed View Article .J Clin Oncol 2006 , 24 : 3984 - 3990 .", "label": "", "metadata": {}, "score": "87.915085"}
{"text": "Statistical analysis .PSA responses were compared with a chi - square test .OS was determined according to the Kaplan - Meier method and compared with the log - rank test .", "label": "", "metadata": {}, "score": "88.07863"}
{"text": "ARC is highly reliable because it was developed from 656 CRPC patients who were administered DTX and was also internally validated in 333 CRPC patients who were administered mitoxantrone among the 1006 CRPC patients in the TAX327 study [ 1 ] .", "label": "", "metadata": {}, "score": "88.23439"}
{"text": "Samples were analyzed using a titer - based , bridging immunoassay developed and validated to detect ADAs in human serum .Samples with positive antibody levels were further analyzed using a validated , non - quantitative ligand binding assay to detect neutralizing antibodies Ab ) .", "label": "", "metadata": {}, "score": "88.24617"}
{"text": "845 - 850 , 2000 .View at Google Scholar \u00b7 View at Scopus .P. Poortmans , A. Bossi , K. Vandeputte et al . , \" Guidelines for target volume definition in post - operative radiotherapy for prostate cancer , on behalf of the EORTC Radiation Oncology Group , \" Radiotherapy and Oncology , vol .", "label": "", "metadata": {}, "score": "88.25615"}
{"text": "Currently , no data are available outlining outcomes after this pragmatic approach in MBC .The main objectives were to evaluate overall response ( ORR ) , time to progression ( TTP ) , overall survival ( OS ) and toxicity at reintroduction of docetaxel .", "label": "", "metadata": {}, "score": "88.56797"}
{"text": "A multivariate analysis revealed that the ARC and PSA doubling time were independent prognostic factors .Conclusions .Most of CRPC patients were classified into good - risk group according to the ARC and the ARC could predict prognosis in DTX - treated CRPC patients .", "label": "", "metadata": {}, "score": "88.72922"}
{"text": "No preview \u00b7 Article \u00b7 Sep 2013 \u00b7 Journal of B.U.ON . : official journal of the Balkan Union of Oncology [ Show abstract ] [ Hide abstract ] ABSTRACT : Despite the utility of newer antidepressants for alleviating hot flashes , antidepressants do not work adequately enough in many patients .", "label": "", "metadata": {}, "score": "88.9805"}
{"text": "View at Google Scholar .F. E. Lecouvet , D. Geukens , A. Stainier et al . , \" Magnetic resonance imaging of the axial skeleton for detecting bone metastases in patients with high - risk prostate cancer : diagnostic and cost - effectiveness and comparison with current detection strategies , \" Journal of Clinical Oncology , vol .", "label": "", "metadata": {}, "score": "89.04076"}
{"text": "Brain metastasis develops late in the period of colorectal cancer and prognosis in these patients is poor .However , early screening of brain metastases in patients with lung metastasis may improve survival outcomes with new treatment modalities .", "label": "", "metadata": {}, "score": "89.15984"}
{"text": "Table 3 : Characteristics and results of retrospective reports on salvage RT . .A large multi - institutional retrospective study by Stephenson et al .", "label": "", "metadata": {}, "score": "89.21556"}
{"text": "[ Show abstract ] [ Hide abstract ] ABSTRACT : Purpose : Exposure to all active agents may be more important than specific sequence of drug administration in the treatment of patients with metastatic colorectal cancer ( mCRC ) .", "label": "", "metadata": {}, "score": "89.31839"}
{"text": "Patients on steroids had to discontinue them before starting bevacizumab .Patients who were on LHRH agonists were required to continue the use of this therapy .", "label": "", "metadata": {}, "score": "89.58046"}
{"text": "PubMed View Article .Eur J Surg Oncol 2009 , 35 : 123 - 128 .PubMed View Article .J Urol 2008 , 180 : 904 - 909 .", "label": "", "metadata": {}, "score": "89.80292"}
{"text": "N Engl J Med 2004 , 351 : 1513 - 1520 .PubMed View Article .Lancet 2010 , 364 : 1147 - 1154 .View Article . :", "label": "", "metadata": {}, "score": "89.83378"}
{"text": "MDP , RH , VD , JK , DP , AH , MJE revised it critically for important intellectual content .All authors have given final approval of the version to be published .", "label": "", "metadata": {}, "score": "89.93224"}
{"text": "Estimates of All - Cause Mortality .Comparisons of the estimates of all - cause mortality between groups were made by log - rank test .", "label": "", "metadata": {}, "score": "89.99541"}
{"text": "Furthermore , risk of osteonecrosis of jaw was 5 % and the quality - of - life impact of this adverse event on asymptomatic patient , needs to be seriously considered .", "label": "", "metadata": {}, "score": "90.10337"}
{"text": "We concluded that bevacizumab may be effective in all subgroups of patients with mCRC .Furthermore , bevacizumab with combination chemotherapy may be superior to combination chemotherapy only as the first - line treatment of patients with mCRC and pulmonary metastasis .", "label": "", "metadata": {}, "score": "90.22939"}
{"text": "11 , pp .3461 - 3467 , 1999 .View at Google Scholar \u00b7 View at Scopus . E. Lee and J. Wang , Statistical Methods for Survival Data Analysis , John Wiley & Sons , New York , NY , USA , 3rd edition , 2003 .", "label": "", "metadata": {}, "score": "91.05234"}
{"text": "In this study , we aimed to explore the second - line efficiency of capecitabine and oxaliplatin ( XELOX ) in patients with advanced pancreatic cancer who have received gemcitabine - based first - line therapy .", "label": "", "metadata": {}, "score": "91.07395"}
{"text": "AE were collected at regular intervals throughout the study then graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events ( NCI CTCAE v.3.0 ) .", "label": "", "metadata": {}, "score": "91.18176"}
{"text": "In this study , we evaluated the impact of obesity on clinical outcomes of TNBC .Methods : The data of breast cancer patients admitted to our department were collected .", "label": "", "metadata": {}, "score": "91.198006"}
{"text": "FACT - P total score is the sum of the 5 subscores .It ranges from 0 to 156 with higher score indicating better quality of life .", "label": "", "metadata": {}, "score": "91.304886"}
{"text": "Thus , the development of an accurate risk classification that can identify the CRPC patient group in which DTX would be effective is urgently warranted .", "label": "", "metadata": {}, "score": "91.71444"}
{"text": "59 - 66 , 2008 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .C. Kim - Sing and T. Pickles , \" Intervention after PSA failure : examination of intervention time and subsequent outcomes from a prospective patient database , \" International Journal of Radiation Oncology Biology Physics , vol .", "label": "", "metadata": {}, "score": "92.031815"}
{"text": "Therefore , data and discussion of these trials have to be interpreted carefully , and can only be transferred into modern radiation oncology with caution .", "label": "", "metadata": {}, "score": "92.3544"}
{"text": "Patient Characteristics .A total of 16 patients were enrolled in the study from December , 2007 to November , 2010 in three hospitals in Detroit , Michigan in the United States .", "label": "", "metadata": {}, "score": "92.35886"}
{"text": "View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .J. F. Piccirillo , R. M. Tierney , I. Costas , L. Grove , and E. L. Spitznagel Jr. , \" Prognostic importance of comorbidity in a hospital - based cancer registry , \" Journal of the American Medical Association , vol .", "label": "", "metadata": {}, "score": "92.46474"}
{"text": "Authors ' Affiliations .Department of Urology , Jichi Medical University .References .N Engl J Med 2004 , 351 : 1502 - 1512 .", "label": "", "metadata": {}, "score": "92.497284"}
{"text": "Time to SRE was defined as the time from the date of randomization to the date of occurence of the first event defining a SRE or death due to any cause , whichever occurred first .", "label": "", "metadata": {}, "score": "92.59541"}
{"text": "Continuous covariates were compared using a Wilcoxon rank sum test [ 10 ] .Risk of All - Cause Mortality .Univariable and multivariable Cox regression analyses [ 11 ] were performed to identify factors associated with the risk of death following PSA failure .", "label": "", "metadata": {}, "score": "92.705414"}
{"text": "With .Statistical graphics were used to display the PSA response distribution ( via a waterfall plot ) , and the statistics of the PSA distributions at various time points ( via a multiple box plot ) .", "label": "", "metadata": {}, "score": "93.213104"}
{"text": "No treatment - related deaths were seen .MVAC and AC are active regimens in the treatment of advanced / recurrent or metastatic endometrial cancer .", "label": "", "metadata": {}, "score": "93.34211"}
{"text": "Salvage radiotherapy , on the other hand , is given upon biochemical relapse and is the preferred option , by many centers as it does not include patients who might be cured by surgery alone .", "label": "", "metadata": {}, "score": "93.87088"}
{"text": "Conclusions .An unfavourable prognosis after PSA progression during initial HT needs to be considered in the decision process before local prostate radiotherapy .Results from other centres are needed to validate our findings .", "label": "", "metadata": {}, "score": "94.14379"}
{"text": "Low - dose megestrol acetate is well tolerated and can substantially decrease the frequency of hot flashes in women and men .[ Show abstract ] [ Hide abstract ] ABSTRACT :", "label": "", "metadata": {}, "score": "94.47455"}
{"text": "All other treatment - related AE of grade 2 or worse are summarized in Table 2 .The most common AE was hypertension .Two patients developed grade 3 hypertension requiring dose adjustment of their antihypertensive drugs .", "label": "", "metadata": {}, "score": "95.08536"}
{"text": "75 mg / m\u00b2 , 1 hour IV on Day 1 of each 3-week cycle ( immediately after Aflibercept or placebo ) .Other Name : Taxotere \u00ae .", "label": "", "metadata": {}, "score": "95.348465"}
{"text": "ARC was also reported to be able to classify PSA response in CRPC patients , although this system was principally aimed at classifying OS [ 10 ] .", "label": "", "metadata": {}, "score": "95.44809"}
{"text": "[ Show abstract ] [ Hide abstract ] ABSTRACT : While the over - representation of the elderly in the breast cancer population is projected to dramatically increase within the next two decades , data on chemotherapy for elderly patients with metastatic breast carcinoma ( MBC ) remain very limited .", "label": "", "metadata": {}, "score": "96.17721"}
{"text": "A univariate analysis conducted with the log - rank test revealed significant associations between OS and 4 factors ( PSA at DTX initiation , PSADT , ECOG performance status , and ARC ) .", "label": "", "metadata": {}, "score": "96.41701"}
{"text": "PubMed View Article .Radiat Oncol 2012 , 7 : 14 .PubMed View Article .Lancet Oncol 2010 , 11 : 1066 - 1073 .", "label": "", "metadata": {}, "score": "96.4544"}
{"text": "The objective of this study was to examine the clinical significance of ARC through external validation in DTX - treated Japanese CRPC patients .Methods .", "label": "", "metadata": {}, "score": "97.08255"}
{"text": "None of the authors report any financial or personal relationships which might inappropriately bias this work .Acknowledgment .Neil E. Martin and Paul L. Nguyen receive funding from Prostate Cancer Foundation Young Investigator Awards .", "label": "", "metadata": {}, "score": "97.41125"}
{"text": "DTX and OCT combination induced apoptosis in both breast and prostate cancer cells in a concentration- and time - dependent manner .Moreover , combination treatment resulted in inhibition of anti - apoptotic proteins such as Bcl-2 and Bcl - xL and induction of pro - apoptotic proteins Bax , Cytochrome c and IAPs in all of the tested cancer cell lines .", "label": "", "metadata": {}, "score": "98.10248"}
{"text": "To determine the pharmacokinetics of intravenous ( IV ) aflibercept in this population ; .Allocation : Randomized Endpoint Classification : Efficacy Study Intervention Model : Parallel Assignment Masking : Double Blind ( Subject , Caregiver , Investigator )", "label": "", "metadata": {}, "score": "99.17561"}
{"text": "Armstrong , the developer of the ARC , externally validated ARC and the above - mentioned nomograms in CRPC patients who were administered DTX [ 16 ] and indicated the superior but insufficient discriminatory abilities and necessary improvements of these tools .", "label": "", "metadata": {}, "score": "99.29312"}
{"text": "No data have been available to address whether the combination of both agents would more effectively alleviate hot flashes , compared with gabapentin alone , in patients with inadequate hot flash control with an antidepressant alone .", "label": "", "metadata": {}, "score": "100.673355"}
{"text": "985 - 990 , 2006 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus [ Show abstract ] [ Hide abstract ] ABSTRACT : Docetaxel is a major drug in metastatic breast cancer ( MBC ) treatment .", "label": "", "metadata": {}, "score": "101.507"}
{"text": "The authors declare that they have no competing interests .Authors ' contributions .MP , MJE have made substantial contributions to conception and design ; MP , MDP , RH , VD , JK , MJE have made substantial contributions to acquisition of data ; MP , MDP , RH , DP , AH , MJE to analysis and interpretation of data .", "label": "", "metadata": {}, "score": "101.74736"}
{"text": "Gabapentin seems to decrease hot flashes by approximately 50 % in women with inadequate hot flash control who were using an antidepressant .This study saw no significant additional hot flash reduction from continuation of the antidepressant .", "label": "", "metadata": {}, "score": "101.87507"}
{"text": "There was one treatment - related death .CONCLUSIONS This regimen of EMP plus weekly paclitaxel was an active and well tolerated treatment for patients with AIPC .", "label": "", "metadata": {}, "score": "102.05449"}
{"text": "Funding .This research was supported in part by Genentech , Inc. and the NIH Cancer Center Support Grant CA-22453 .Conflict of Interests .Dr Vaishampayan received honoraria and research support from Genentech Inc ..", "label": "", "metadata": {}, "score": "102.09225"}
{"text": "KN is responsible for the statistical analyses .Conclusions have been drawn mainly by KN and TM .TM has given final approval of the version to be published .", "label": "", "metadata": {}, "score": "102.345474"}
{"text": "PPI scale is a self - report 0 - 5 scale to assess pain intensity - a score 0 reflects no pain , a score 5 reflects excruciating pain .", "label": "", "metadata": {}, "score": "102.76845"}
{"text": "However , results from other centres are needed to validate our findings .Declarations .Acknowledgements .We would like to thank the staff who took care of our patients ' needs , and who were involved in gathering , documenting , verifying , forwarding , and processing the clinical data .", "label": "", "metadata": {}, "score": "103.1624"}
{"text": "The Armstrong risk classification ( ARC ) , which classifies CRPC patients into 3 groups , is superior ; however , its usefulness remains unclear , and further external validation is required before clinical use .", "label": "", "metadata": {}, "score": "103.2071"}
{"text": "Due to the heterogeneous disease profile of TNBC , larger randomized studies will be needed to clarify the exact role of obesity in TNBC .[ Show abstract ] [ Hide abstract ] ABSTRACT : Docetaxel ( DTX ) is widely used for the treatment of metastatic prostate and breast cancers .", "label": "", "metadata": {}, "score": "103.41316"}
{"text": "Conclusions .Most of CRPC patients were classified into good - risk group according to the ARC and the ARC could predict prognosis in DTX - treated CRPC patients .", "label": "", "metadata": {}, "score": "103.65489"}
{"text": "Postoperative Radiotherapy after Radical Prostatectomy : Indications and Open Questions . 1 Department of Radiation Oncology , Inselspital , Bern University Hospital , University of Bern , Freiburgstrasse , 3010 Bern , Switzerland 2 Department of Radiation Oncology , Kantonsspital Graub\u00fcnden , 7000 Chur , Switzerland 3 Department of Radiation Oncology , University Hospital Basel , 4031 Basel , Switzerland .", "label": "", "metadata": {}, "score": "105.64052"}
{"text": "It seems reasonable to follow the guidelines on target volume definition from the EORTC Radiation Oncology Group , to reach an optimal compromise on both target volume coverage and sparing of critical organs and structures at risk .", "label": "", "metadata": {}, "score": "107.58387"}
{"text": "[ Show abstract ] [ Hide abstract ] ABSTRACT : Brain metastasis in colorectal cancer is highly rare .In the present study , we aimed to determine the frequency of brain metastasis in colorectal cancer patients and to establish prognostic characteristics of colorectal cancer patients with brain metastasis .", "label": "", "metadata": {}, "score": "108.55791"}
{"text": "20 , pp .2441 - 2447 , 2004 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .M. Hollander and D. Wolfe , Nonparametric Statistical Methods Wiley Series in Probability and Statistics , John Wiley & Sons , New York , NY , USA , 2nd edition , 1999 .", "label": "", "metadata": {}, "score": "109.39435"}
{"text": "Thus , there is an urgent need for new therapeutic options .Octreotide ( OCT ) is a synthetic somatostatin analog that induces apoptosis in different cancer cell lines in vitro .", "label": "", "metadata": {}, "score": "109.86821"}
{"text": "4 , pp .433 - 439 , 2005 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .292 , no . 7 , pp .", "label": "", "metadata": {}, "score": "114.28122"}
{"text": "6 , pp .472 - 479 , 2006 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .24 , no .", "label": "", "metadata": {}, "score": "114.46086"}
{"text": "MVAC has substantial toxicity compared to AC and is not substantially superior to AC .MVAC can not be considered as a standard for treatment in this patient population .", "label": "", "metadata": {}, "score": "114.67891"}
{"text": "28 , no . 7 , pp .1106 - 1111 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .", "label": "", "metadata": {}, "score": "115.88536"}
{"text": "74 , no . 3 , pp .643 - 647 , 2009 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .", "label": "", "metadata": {}, "score": "119.70607"}
{"text": "64 , no .4 , pp .760 - 764 , 2004 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .", "label": "", "metadata": {}, "score": "120.2991"}
{"text": "[ Show abstract ] [ Hide abstract ] ABSTRACT : Colorectal cancer ( CRC ) is among the most frequently diagnosed cancers and a major cause of cancer - related mortality worldwide .", "label": "", "metadata": {}, "score": "120.82851"}
{"text": "27 , pp .4178 - 4186 , 2007 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .26 , no . 1 , pp .", "label": "", "metadata": {}, "score": "120.84192"}
{"text": "22 , pp .3281 - 3287 , 2007 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .29 , supplement 7 , p. 135 , 2011 .", "label": "", "metadata": {}, "score": "120.963974"}
{"text": "71 , no . 2 , pp .346 - 350 , 2008 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .", "label": "", "metadata": {}, "score": "121.315895"}
{"text": "Talk with your doctor and family members or friends about deciding to join a study .To learn more about this study , you or your doctor may contact the study research staff using the Contacts provided below .", "label": "", "metadata": {}, "score": "121.75132"}
{"text": "\u00a9 2004 American Cancer Society .Received 18 March 2012 ; Accepted 9 April 2012 .Academic Editors : S. Honor\u00e9 and B. Luber .Copyright \u00a9 2012 Shin Ogita et al .", "label": "", "metadata": {}, "score": "122.61999"}
{"text": "PubMed View Article .Eur Urol 2008 , 53 : 323 - 332 .PubMed View Article .Pre - publication history .Copyright .\u00a9 Nakano et al . ; licensee BioMed Central Ltd. 2014 .", "label": "", "metadata": {}, "score": "124.98604"}
{"text": "Conflict of Interests .The authors have no actual or potential conflict of interests related to this paper .There are no financial disclosures from any author .", "label": "", "metadata": {}, "score": "126.26868"}
{"text": "Department of Radiation Oncology , RWTH Aachen University .Department of Urology , RWTH Aachen University .References .Eur Urol 2011 , 59 : 61 - 71 .", "label": "", "metadata": {}, "score": "132.12433"}
{"text": "PubMed View Article .Copyright .\u00a9 Pinkawa et al . ; licensee BioMed Central Ltd. 2012 .This article is published under license to BioMed Central Ltd.", "label": "", "metadata": {}, "score": "133.05537"}
{"text": "Acknowledgement .We thank Mayumi Takasawa for the assistance with manuscript preparation .Competing interests .The authors declare that they have no competing interests .", "label": "", "metadata": {}, "score": "141.63882"}
{"text": "View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .164 , no . 1 , pp .101 - 105 , 2000 .", "label": "", "metadata": {}, "score": "142.6214"}
{"text": "Academic Editor :Jay P. Ciezki .Copyright \u00a9 2012 Pirus Ghadjar et al .This is an open access article distributed under the Creative Commons Attribution License , which permits unrestricted use , distribution , and reproduction in any medium , provided the original work is properly cited .", "label": "", "metadata": {}, "score": "153.5841"}
{"text": "Academic Editor : Michael Zelefsky .Copyright \u00a9 2014 Neil E. Martin et al .This is an open access article distributed under the Creative Commons Attribution License , which permits unrestricted use , distribution , and reproduction in any medium , provided the original work is properly cited .", "label": "", "metadata": {}, "score": "157.49756"}
